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ABSTRACT
Helicobacter pylori infection is associated with gastritis and peptic ulceration.
Epidemiological studies indicated that individuals of blood group O or non-secretors
of their ABO blood group antigens are over represented among patients with peptic
ulcers.
The aims of the study were: 1) to assess blood group and secretor status of local
patients with peptic ulcer disease; 2) to determine if H. pylori binds to blood group
antigens and if environmental factors such as fasting or smoking affect the binding;
3) to isolate bacterial adhesins that bind to the blood group antigens; 4) to determine
if there are differences in the immune or inflammatory responses to H. pylori
associated with ABO blood group or secretor status.
There was a higher proportion of group O and non-secretors in the local patient
group. In studies in which flow cytometry was used to assess bacterial binding to
buccal epithelial cells or the gastric adenocarcinoma cell line (Kato III), binding of
H. pylori was inhibited by pretreatment of the cells with monoclonal antibodies
against Lewisa (Lea), Lewis*5 (Le*5) and H type 2 (the antigen of blood group O).
Binding indices of H. pylori to buccal epithelial cells correlated with binding indices
for H type 2 and Le*5 but not with Lea, suggesting the terminal fucose moieties of H
type 2 and Lewis*5 are important epitopes for bacterial binding.
Binding of H. pylori to buccal epithelial cells from smokers was significantly
higher than to cells from non-smokers among patients referred to the gastroscopy
clinic. In other experiments with cells from healthy volunteers, binding of H. pylori
to cells from smokers was higher than to cells of non-smokers but the differences
were not significant. Because each patient had fasted for approximately 12 hours
before the cells were collected at the clinic, the effects of fasting and smoking were
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examined with buccal cells from 15 pairs of smokers and non-smokers when fasting
during Ramadan and after the fast when the donors were eating and drinking
normally. In this group, binding of H. pylori and expression of H type 2 were
significantly lower among the smokers. For both the patients and healthy groups,
the levels of H type 2 expressed on buccal epithelial cells correlated with binding of
H. pylori, and H type 2 is expressed in significantly greeter levels on cells of group
O.
A protein of approximately 61 kDa was obtained by affinity adsorption with
synthetic Lewisa, Lewis^ or H type 2 antigens conjugated to Synsorb beads. The
amount of material obtained from the Synsorb eluates reflected the amount of the
biotinylated blood group antigens bound to the bacteria assessed by whole cell
ELISA or dot blot; more H type 2 bound to whole cells of H. pylori, its outer
membrane proteins or the 61 kDa adhesin than Le^ while Lea bound the least
effectively. The studies of inflammatory mediators released from human buffy
coats in response to H. pylori or the purified adhesin showed that blood group O
individuals produced significantly higher levels of IL-6, TNF and nitric oxide.
Higher levels of colonization by H. pylori are significantly associated with
duodenal ulceration. The greater binding to H type 2 might contribute to the excess
of individuals of blood group O in the patient population. The greater binding of
Le^ found in the mucus of secretors to most strains compared with Lea might more
effectively block some of the bacterial adhesins, thereby reducing density of
colonisation among secretors. Differences in inflammatory responses to H. pylori
need to be further investigated with reference to the associations of peptic ulceration
with group O and gastric carcinoma with group A.
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Chapter 1 General introduction
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1- Historical background
It is over a century since Bizzozero first described in 1893 spiral microorganisms in
the gastric mucosa of dogs. In the early years of this century, similar organisms were
found in the gastric contents of patients with ulcerative carcinoma and other reports
confirmed these findings, noting also the absence of these organisms in healthy
people [reviewed by Owen, 1995].
Helicobacter pylori was identified first in Southampton by Steer in 1975. He
reported spiral bacteria on gastric mucosa, deep in the mucus layer of patients with
gastric ulceration [Steer and Colin-Jones, 1975], The organism seen on the mucosa
was a spiral bacterium and it is now assumed that the bacteria were probably H.
pylori. Electron micrographs of spiral bacteria in large numbers on gastric epithelial
cells were published by Steer in 1984 [Steer, 1984], In 1983 Marshall and
colleagues reported a histological association between a spiral bacterium, peptic
ulcer and gastritis. The following year the organism was found to have culture
properties similar to members of the Campylobacter group. The taxonomic
classification evolved from the initial term Campylobacter-like, through
Campylobacter pyloridis, finally in 1989 to Helicobacter pylori [Goodwin et al.,
1989],
1.1- Helicobacter genus
The culture of H. pylori stimulated interest in the microbiology of the human
stomach. The result was that a number of related bacteria from other animals have
been cultured and shown to belong to the same genus as H. pylori by 16S rRNA
sequencing, DNA hybridisation, or use of genus specific probes. Helicobacter
isolates have been found in a diverse group of animals species (Table 1.1)
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Table 1.1 Helicobacter genus cultured from different animal species
Host Helicobacter Species Reference
rat and mouse Helicobacter muridarum Lee et al., 1992
cat and dog Helicobacterfelis Paster et al., 1991]
pigtailed macaque Helicobacter nemestrinae Bronsdon et al., 1991
cheetah Helicobacter acinonyx Eaton etal., 1991
ferret Helicobacter mustela Fox et al., 1986
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Two human pathogens associated with gastroenteritis were originally put in the
Campylobacter genus but are now know as Helicobacter cinaedi and Helicobacter
fennelliae [Vandamme et al., 1991]. Helicobactermustela, the second species to be
cultured, is a natural inhabitant of the ferret stomach [Fox et al., 1986]. It's
morphology is different from other Helicobacter species being a short rod shaped
organism; however, it shares the major common biochemical and physiological
features of the Helicobacter gastric group.
Flexispira rappini has been found in human beings with gastroentritis and in the
stomachs of beagle dogs [Henry et al., 1987], Although this organism shows some
differences from H. pylori, it possesses urease and genotypically should be in the
Helicobacter genus as Helicobacter rappini [Lee et al., 1992; Vandamme et al.,
1991]. The most widespread of the spiral gastric bacteria that colonise the mucosa
is the bacterium currently known as Gastrospirillum hominis [McNulty et al., 1989].
This bacterium is found in very large numbers in the stomach of cats, dogs and
cheetahs. The organism gets its name from being associated with gastritis in a small
number of humans [Lee et al., 1988]
1.2 Characteristics ofH. pylori
H. pylori is a Gram-negative, unipolar, multiflagellate, spiral organism with bluntly
rounded ends, measuring 0.5 to 1.0 pm in width and 2.5 to 4.0 pm in length
[Megraud, 1989; Goodwin and Armtrong, 1990]. The organism might occasionally
contain bacteriophages [Schmid et al., 1990], H. pylori colonises gastric type
mucosa and is found primarily in the antrum of the stomach. It is also seen in the
duodenum within areas of gastric metaplasia and in the fundus [Steer, 1984; Caselli
et al., 1988].
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The organism produces large amounts of urease which is present within and on the
bacterial surface [Dick, 1990; Blaser et al., 1990]. Urease cleaves urea to produce
ammonia which creates an alkaline environment that aids survival of the bacteria in
the acidic environment of the gastric lumen and mucosa [Goodwin et al., 1986;
Hazell and Lee, 1986]. Prolonged culture gives rise to the coccoidal forms, which
also appear after exposure to oxygen [Jones and Curry, 1992] . It is assumed that
these forms are indicative of a dormant state and assist the survival of the organism
in the environment [Jones and Curry, 1992], The coccoidal forms of H. pylori are
formed when the outer envelope appears to separate and ceases to keep pace with
cell growth leading to folding of the inner cytoplasmic rod [Jones and Curry, 1992]
1.3 - Classification
H. pylori strains closely resemble one another in morphology, structure, physiology
and biochemical characteristics. None of the common biochemical tests performed
in clinical microbiology laboratories can distinguish between H. pylori strains
[reviewed by Blaser, 1994]. Various phenotypic characteristics and a range of
techniques have been tested in an effort to find a basis for discriminating logically
between isolates of H. pylori.
I.3.1 - Phenotyping methods
1.3.1.1 - Biotyping
H. pylori appears to be a homogeneous species [Megraud, 1989]. Biotyping using
preformed enzyme activity only provides a low degree of discrimination between
isolates of H. pylori. Among 126 H. pylori isolates from human and animals
(monkey, baboon and pig), there were four biotypes detected by API Zym system
using five enzymes. Among the strains from 10 countries, there was one
predominant group (85%), biotype II (bio-type 2). They all characteristically
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produced alkaline phosphatase, acid phosphatase, leucine arylamidase and naphthol
phosphohydrolase, but not esterase C4 or C8. The other three biotypes which were
less frequently encountered were detected with similar frequencies 4% type I, 6%
type III and 5% type IV [Owen and Desai, 1990]
1.3.1.2 - Serotyping
The carbohydrate portion of lipopolysaccharides (LPS) consists of a core
oligosaccharide which is conserved among the members of a species and more
variable polysaccharide side-chains. The polysaccharide side chain can be of either
variable or uniform length units. There is marked diversity in the length and
antigenicity of the polysaccharide side chains among H. pylori strains [Perez-Perez
and Blaser, 1987].
Lior described five serogroups based on heat labile (flagellar) antigens among 87
isolates investigated. Subsequent data showed that most strains appear to belong to
the same serogroup [Lior, 1991].
The antigenicity of H. pylori LPS has been investigated and the LPS antigens of H.
pylori were sufficiently diverse for potential use as the basis of an O-antigen (heat-
stable) serotyping system [Mills et al., 1992],
1.3.1.3 - Haemagglutination
Haemagglutination of H. pylori isolates with erythrocytes from 11 different animal
species resulted in 9 haemagglutination patterns [Wadstrom et al., 1990]. In another
study, strains were classified into 3 major HA classes by using haemagglutination
inhibition. Haemagglutination of 31% of strains in class I was inhibited by different
combinations of N-acetylneuraminlactose (NANLac), orosomucoid or fetuin but not
by asialofetuin. Strains in class II (38%) exhibited a different receptor specificity
binding to different combinations of NANLac, orosomucoid and fetuin as well as
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asialofetuin. Strains in class III (31%) showed no inhibition by these materials
[Lelwala-Guruge et al., 1992].
1.3.1.4 - Outer membrane proteins
The direct molecular characterisation of patterns of certain outer membrane protein
(OMP) classes provides a means of comparing and typing isolates of H. pylori. H.
pylori strains have been found to contain six major OMP bands with molecular
masses of approximately 23, 27, 46, 58, 61 and 66 kDa [Morgan et al., 1991]. A
group of closely related high molecular weight proteins which migrate between 120
and 140 kDa were not present in all strains [Perez-Perez and Blaser, 1987; Apel et
al., 1988]. The cytotoxin associated gene A (cagA) that encodes these proteins has
been cloned [Tummuri et al., 1993], and it has been shown that about 60% of H.
pylori strains posses the gene. The cagA gene was the first H. pylori gene used to
differentiate between strains. H. pylori OMPs differ between the strains and a
typing scheme based on four bands 31, 70, 90, and 110 kDa detected 16 typing
groups with a wide scatter of strains among the groups [Goodwin and Armstrong,
1990],
1.3.1.5 - Immunoblotting
Immunoblotting with a rabbit antiserum raised against the protein extract of a
selected H. pylori strain produced nine types, each defined on the basis of the
presence or absence of 11 protein bands [Burnie et al., 1988]. An immunoblot
fingerprinting technique showed that H. pylori had 4-6 major immunogenic
polypeptides in the 48 - 84 kDa region. Differences in minor antigenic bands in the
84 - 180 kDa regions allowed differentiation between isolates [Clayton et al., 1991].
1.3.1.6 - Protein profiles
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Typing of H. pylori isolates based on analysis of whole cell protein fingerprints
obtained from high resolution one-dimensional sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE) showed that virtually all the strains
of H. pylori tested had complex but stable protein patterns of 35 to 40 discrete bands
with molecular weights of 20 to 100 kDa [ Costas et al., 1991]. Reproducible
quantitative and qualitative differences in the bands were used to distinguish
between strains [Owen et al., 1989]. Similar patterns were found only between
isolates from the same individuals [Costas et al., 1991].
1.3.2 - DNA-based typing methods
DNA based typing methods indicate there is considerable diversity among H. pylori
isolates.
1.3.2.1 - Restriction endonuclease digest patterns
DNA digest patterns have been used widely to compare isolates of H. pylori from
different individuals, to distinguish multiple isolate sets before and after treatment
[Beji et al., 1989; Simor et al., 1990; Oudbier et al., 1990; Owen et al., 1990], to
compare isolates from dental plaque and stomach [Shames et al., 1989] and isolates
from different individuals in the same family [Nwokolo et al., 1992]. Digest
patterns are highly complex with multiple band patterns. It is difficult to quantify
similarities between strains because most strains from different individuals appear to
have unique DNA digest patterns. One possible approach is to use the larger sized
fragments of 10 to 20 kb to provide a signature pattern for high level discrimination
and to subgroup the isolates [Owen et al., 1990]. Another approach is to compare
different isolates by pulsed field gel electrophoretic analysis of DNA digested with
low frequency cutting enzymes such as those from Nocardia otitidis caviarum
(NotI) and Nocardia rubra (.Nrul) [Taylor et al., 1992].
10
1.3.2.2 - Southern blot hybridization analysis
Ribosomal RNA gene patterns (ribopatterns) provide a simpler yet highly
discriminatory basis for strain identification. The pattern of bands reflects the
location of restriction sites in and around the two copies of the small 16S and large
23S rRNA subunit genes [Owen, 1989]. Several investigators have used ribotyping
to study pre- and post-treatment isolates of H. pylori [Tee et al., 1992; Rautelin et
al., 1994], The ribopatterns obtained with Haemophilus aegypticus (Haell) and
Haemophilus influenzae (HindlH) are highly discriminatory with distinctive profiles
of five bands with sizes between 1 and 10 kb. Isolates from the same patients have
similar genotypes, whereas strains from different individuals had different profiles
except some family members in which similar patterns were observed [Bamford et
al., 1993; Nwokolo et al., 1992].
1.4 - Epidemiology of infection
1.4.1 - Transmission of infection
The mode of transmission of H. pylori is unknown but the geographic and social
patterns of H. pylori infection are consistent with human to human transmission via
either the faecal - oral or oral - oral route. Evidence for person-to-person
transmission include: infection among gastroenterologists performing upper
endoscopy with presumed exposure to gastric secretions containing H. pylori
[Mitchell et al., 1989; Lin et al., 1994]; transmission of H. pylori within families
[Mitchell et al., 1987; Malaty et al., 1991; Lin et al., 1991]; and high prevalence of
H. pylori infection in institutionalised mentally handicapped patients compared with
control populations [Lambert et al., 1990; Berkowicz and Lee, 1987]. Direct
evidence was obtained in studies in which volunteers who ingested the organism
developed acute upper gastrointestinal symptoms and were colonized with H. pylori
[Marshall let al., 1985; Morris and Nicholson, 1987],
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1.4.1.1 - Faecal-oral transmission
There is a constant production of mucus and a rapid turnover of gastric mucosa in
the stomach. H. pylori can be found in gastric juice and is constantly eliminated from
the intestine. It can survive in faeces and can be excreted into the environment.
Faeces or anything contaminated (e.g. water or food) could be the vehicle of
transmission following the model of Shigella species or Salmonella typhi
[summarised by Megraud, 1995]
H. pylori has never been cultured from faecal specimens using the standard
protocols, but large fresh stool samples suspended in a microaerobically maintained
buffer were used to culture of H. pylori [Thomas et al., 1992; Kelly et al., 1994], It
has been also detected in faeces by the polymeriase chain reaction (PCR). An
amplification product was demonstrated in the faeces of 26 of 29 patients [Mapstone
et al., 1993]. The prevalence of H. pylori infection has been directly related to the
source of drinking water in Lima, Peru [Klein et al., 1991] and to consumption of
uncooked vegetables and uncooked shellfish in Chile [Hopkins et al., 1993].
I.4.1.2 - Oral-oral transmission
Support for oral-oral transmission of H. pylori has also come from the detection of
H. pylori DNA in the saliva, gastric juice and dental plaque of infected patients by
PCR [Valentine et al., 1991; Mapstone et al., 1993; Banatvala et al., 1993]. It is
suggested that reflux of gastric juice containing H. pylori could reach the oral cavity
and the bacteria could colonise the mouth, in particular the microaerophilic
environment of the dental plaque. Saliva could be the vehicle of transmission
[summarised by Megraud, 1995].
I.4.2 - Age is a risk factor for infection
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Epidemiological studies have relied upon serological evidence of a specific immune
response to H. pylori antigens. The prevalence of H. pylori infection related to age
in different communities shows an age-dependent increase and appears to fall into
two groups. In the first group there is a high incidence of acquisition of infection
during childhood (developing countries). In the second group, the prevalence of H.
pylori infection increases with age (developed countries).
1.4.2.1 - Prevalence ofH. pylori infection in developing countries
Most epidemiological studies on prevalence of H. pylori in different population used
enzyme linked immunosorbent assays (ELISA) to detect antibodies to these bacteria,
their outer membrane components or urease. In the Ivory Coast of Africa, 54% of
individuals below the age of 9 years had antibodies to H. pylori and this rose to 70 -
80% throughout adult life [Megraud et al., 1989]. Serum samples from Vietnam
showed that only 13.1% of children below the age of 9 years were antibody positive
but the proportion rose to 43% between the age of 10 - 19 years and to 50 - 80%
during adult life [Megraud et al., 1989]. In rural Thailand the prevalence of
infection was 18% among children aged 5-9 years but reached 55% by 30 years and
75% by 50 years [Perez-Perez et al., 1990]. A study from Belgium investigated the
prevalence of H. pylori antibody in children between 2 and 14 years old. There was
an increase in positivity from 5.4% in the age group 2-8 years to 13.4% in the age
group 8-14 years [Blecker et al., 1993].
The ELISA for immunoglobulin G antibody against the urease antigen of H. pylori
was used for a clinical survey in Saudi Arabia. The prevalence of H. pylori infection
increased rapidly with age from 40% in those aged 5-10 years to more than 70% in
those aged 20 years or more [Al-Moagel et al., 1990], In South Africa, there was an
age-specific increase in the prevalence of H. pylori with 60% seropositive by the age
of 10 years and 94% by the age of 30 years [Sathar et al., 1994]
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1.4.2.2 - Prevalence ofH. pylori infection in developed countries
In developed countries, the presence of H. pylori infection seems to be low in
children and increases gradually with age from 10% in young adults to reach a peak
of 70% by the eighth decade [Rautelin and Kosunen, 1991]. Among asymptomatic
healthy subjects in California, USA, the prevalence of H. pylori infection increased
from 10% in those between the ages of 18 to 29 years to 47% in those between the
ages of 60 to 69 years [Dooley et al., 1989]. Two strains of H. pylori were used in a
serological survey of the Algerian population in France. Results for 277 serum
samples from blood banks and a children's clinic indicated 43% of the children
below the age of 9 years had antibody to the bacteria. The prevalence of antibody
positive individuals rose steadily during adult life reaching a peak of 92% between
the ages of 40 to 49 years [Megraud et al., 1989].
Sera from health centres and emergency rooms in France examined by ELISA
showed few children were infected before the age of 10 years but the proportion
increased gradually to 36.7% in the sixth decade of life [Megraud et al., 1989]. Sera
from blood donors in Finland showed the proportion of donors with IgG antibody
against H. pylori increased from 10% between 18 to 25 years up to 60% in the
donors in the age range of 56 to 65 years [Kosunen et al., 1989]. In London, UK,
the prevalence of IgG antibodies against H. pylori ranged from 9% in those aged less
than 30 to 67% in those aged more than 70 years old [Mendall et al., 1992],
The birth cohort pattern of peptic ulcer disease is found to be similar in all European
countries, USA, Australia and Japan. In relation to gastric ulcers, the birth related
risk involves all ages over 5 years, while in duodenal ulcer it does not start before
the age of 15 years [ Sonnenberg, 1995]. The link between H. pylori associated
antral gastritis and duodenal ulcer disease is weaker in children than it is in adults
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[Oderda et al., 1991; Mitchell et al., 1993]. Most Children with H. pylori infection
do not seem to suffer from symptoms [Gormally et al., 1995].
1.4.3 Socio-economic conditions
Apart from the well known effect of age on prevalence [Graham et al., 1991], it is
agreed that lower socio-economic status is associated with a higher prevalence of H.
pylori infection. This relationship has been found world-wide: USA [Graham et al.,
1991; Smoat et al., 1994]; Chile [Hopkins et al., 1993]; Peru [Klein et al., 1991];
UK [Sitas et al., 1991]; Saudi Arabia [Al-Moagel et al., 1990]; India [Katelaris et
al., 1993]; and South Africa [Louw et al., 1993]. Vietnamese immigrants in
Australia (who are usually in the highest socio-economic class) have a lower
infection rate than Vietnamese blood donors of the same age in Ho Chi Minh city
living under very difficult conditions [Megraud et al., 1989; Dwyer et al., 1988]. In
the US, among healthy children and young adults (age range 3-21 years) the rate of
infection was assessed by the socio-economic status determined by family income.
The rate of infection in families with low incomes was higher than families with
high incomes [Fiedorek et al., 1990], Another study found living conditions during
childhood (e.g., absence of a fixed hot water supply and domestic crowding) were
independent risk factors for H. pylori infection [Mendall et al., 1992],
Several studies make clear that socio-economic status is closely linked to education
level and provide an overall measure of environmental factors such as the general
level of hygiene, water supply, sanitation and crowding in the household [Graham et
al., 1991; Smoat et al., 1994; Al-Moagel et al., 1990; Katelaris et al., 1993; Louw et
al., 1993]. One of the largest studies on the importance of socio-economic status
was the Eurogast study, in which 3194 asymptomatic subjects from 17 different
populations in 13 countries were tested by serology for H. pylori infection. The
incidence of seropositive subjects was 34% in those with tertiary education, 47% in
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those with secondary education and 62% in those who received only primary
education [Eurogast study Group, 1993].
1.4.4 Smoking
Cigarette smoking is a risk factor for the development, maintenance and recurrence
of peptic ulcer disease [Freston, 1989]. There is a positive correlation between the
number of cigarettes smoked and peptic ulceration, especially for duodenal ulcers
(DU) [Friedman et al., 1974; Harrison et al., 1979; McCarthy, 1984], Smoking is
associated with reduction in the healing rate of gastric and duodenal ulcers [Doll et
al., 1958; Korman et al., 1981] and with an increase in recurrence of duodenal ulcers
[Sontag et al., 1984; Korman et al., 1983]. Current cigarette smokers had a higher
rate of infection than non-smokers and ex-smokers [Bateson, 1993]. Martin and
colleagues found smoking increases the risk of DU formation in subjects who are
infected with H. pylori [Martin et al., 1989]. Studies of small numbers of patients
with gastric or duodenal ulcers suggest that smoking is unlikely to promote ulcer
formation in the absence of H. pylori [George et al., 1990; Hui et al., 1986].
The major risk factor for H. pylori infection seems to be the socio-economic status of
the child's family. Children and adult smokers can form a family circle, young
women and their partners who are less well educated and less affluent are most
likely to smoke [Charlton, 1996] and smoking rates are increased among poor people
and less educated people [Valentich, 1994],
1.4.5 ABO blood group and secretor status
The first genetic markers for susceptibility to peptic ulcers were noted in the 195Q's,
well before the observation linking H. pylori infection to the condition. Individuals
of blood group O have a 30 - 40% higher incidence of duodenal ulcer than those of
the other blood groups. Non-secretors, individuals who do not have the water
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soluble form of their ABO blood group antigens in body fluids, are 40 - 50% more
likely to develop a duodenal ulcer than secretors [Aird et al., 1954; McConnell,
1980]. It is known that most patients with duodenal ulcers are colonised with H.
pylori [Tytgat and Rauws, 1990]. Several studies found no association between
serological evidence of H. pylori infection and ABO blood group [Hook-Nikanne et
al., 1990; Loffeld and Stobberingh, 1991]. Mentis and colleagues reported similar
negative findings for ABO blood group and identification of H. pylori by culture or
microscopy; but they found an association for both gastric and duodenal ulcers with
blood group O [Mentis et al., 1991],
Another study showed that non-secretion is a significant risk factor for
gastroduodenal disease but is not associated with the presence of H. pylori in the
antral biopsy of patients with symptoms of dyspepsia in the age range 19 to 70 years
[Dickey et al., 1993]. A clear correlation was found between ABO blood group and
H. pylori infection among patients with rheumatoid arthritis compared with an age
matched group 50 - 66 years. Significantly more patients of blood group O, all of
whom were secretors of ABH substances, had H. pylori in the antral mucosa
compared with patients of the other blood groups. It was concluded that blood group
O individuals run a higher risk of developing a chronic H. pylori infection
[Henriksson et al, 1993], Further studies on the role of ABO blood group and
secretor status in relation to disease rather than infection are required.
I.5 Pathogenic mechanisms ofH. pylori
H. pylori is found in an indent of the apical membrane of mucus cells [Lee et al.,
1985; Steer, 1985; Buck et al., 1986; Chen et al., 1986; Bode et al., 1988] or the
luminal surface of mucus secreting cells within gastric pits. It does not invade the
tissues [Jones et al., 1984; Rollason et al., 1984; Tricottet et al., 1986; Blaser, 1987].
Some of the bacteria are found within the mucus layer or, more usually, between the
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mucus layer and the underlying gastric epithelium [Hazell et al., 1986], The cell
wall of H. pylori contains a lectin [Evans et al., 1988] which selectively binds the
organism to the mucus cell layer and the epithelial cell membrane. Lectins allow H.
pylori to attach tightly to gastric epithelial cells [Slomiany et al., 1989]. After
attaching to the epithelial cells, H. pylori infection leads to polymerisation of actin
below the epithelial cell membrane and generation of a cell structure called
"attachment pedestals" by which it is attached to the plasma membrane [Goodwin et
al., 1986; Smooth al., 1989; Rosenberg et al., 1991].
Virulence factors that allow H. pylori to colonize and survive in the hostile
environment of the stomach which include spiral shape and motility, adaptive
enzymes and proteins and bacterial adherence to gastric mucosal cells. Factors
suggested to contribute directly to disruption of the gastric mucosal barrier include
toxins, humoral responses, cytokines and cell mediated responses of the host.
1.5.1 Spiral shape and motility
Motility of H. pylori is important for penetration of the mucus layer. The curved
structure of H. pylori and its flagella enable it to penetrate the gastric mucous layer
and to colonize the underlying gastric epithelium [Lee et al., 1993]. The most
convincing evidence that motility is a virulence factor for H. pylori comes from
studies in gnotobiotic piglets, the most motile strain of H. pylori which also
produced a vacuolizing cytotoxin was also the most virulent strain [Eaton et al.,
1989],
1.5.2 Urease activity
H. pylori urease is a 500 - 600 kDa protein with a high substrate affinity and is
probably localized in the outer membrane and periplasmic space of the bacteria
[Hazell et al., 1986; Lambert et al., 1995], The bacteria are protected from the
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harmful effect of acid by production of urease which metabolises urea to ammonia
[Hazell et ai, 1986; Marshall et al., 1990; Mobley et al., 1991]. The cytotoxic effect
of ammonia [Blaser, 1990; Cover et al., 1991; Mobley et al., 1991; Triebling et al.,
1991] damages the surrounding cells at the tight junction between epithelial cells and
causes hydrogen ions to diffuse back across the mucus layer [Hazell et al., 1986].
Ammonia also increases antral pH and stimulates gastrin release and acid secretion
[Morris and Nicholson, 1987; Levi et al., 1989; Graham, 1991; Triebling et al.,
1991; Beardshall, 1992] leading to hyperacidity [Levi et al., 1989].
The finding of hypergastrinaemia due to increased pH in the antrum has not been
confirmed by other observers [Chittajallu et al., 1991; Nujumi et al., 1991;
Chittajallu et al., 1992], It has been shown that ammonia can produce functional and
morphological alteration of gastric epithelium in vitro, including reduction of
transmucosal potential differences [Thomson et al., 1989; Murakami et al., 1988],
enhanced back-diffusion of H+ to the epithelial cells [Hazell et al., 1987] and
increased bacterial adherence [Parsons et al., 1984], Ammonia may combine with
neutrophil generated hypochlorous acid (HOC1) to produce cytotoxic products such
as monochloramine and hydroxylamine [Mai et al., 1992].
1.5.3 Other enzymes and proteins
Other toxic factors produced by H. pylori are ureolysin, mucin-degrading enzyme
[Cover et al., 1989], protease, lipases and phospholipases which damage the
integrity of the gastric mucus layer. The mucus becomes more soluble and less
hydrophobic at risk of further damage from acid and pepsin [Slomiany et al., 1987;
Kawano et al., 1990], Catalase inhibits the bactericidal effect of neutrophils
[Babiour, 1978; Tytgat et al., 1991]. Enzymes can also damage the epithelial cell
membrane by breaking down lecithin [Slomiany et al., 1987]. Several non-human
Helicobacter species produce a partially heat labile, pronase inhibiting molecule
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which inhibits acid secretion [Vargas et al., 1991]. H. pylori has been reported to
produce a similar protein capable of inhibiting acid secretion from parietal cells in
vitro [Cave and Vargas, 1989].
1.5.4 Bacterial adherence
Adherence of H. pylori to the epithelial cell surface by adhesion pedestals has been
demonstrated by electron microscopy [Hessey et al., 1990], Specificity of bacterial
adherence implies interaction between bacterial adhesins and mucosal cell receptors.
A variety of putative H. pylori adhesins have been identified, including a fibrillar
haemagglutinin [Evans et al., 1988], a protein that co-purifies with urease by size-
exclusion chromatography [Fauchere and Blaser, 1990], a 31 kDa adhesin [Evans et
al., 1991], a 19.6 kDa pilus-like protein [Doig et al., 1991], a 63 kDa molecule
antigenically similar to exoenzyme S of Pseudomonas [Lingwood et al., 1991] and
an adhesin suggested to bind to the Lewis^ blood group antigen [Boren et al., 1993].
1.5.5 Toxins
The cytotoxin produced by 50 to 60% of H. pylori isolates is a large molecule (>100
kDa) which induces non-lethal vacuolisation of a variety of cell lines [Tee et al.,
1995]. It is heat labile and protease sensitive [Leunk et al., 1988; Cover et al.,
1990]. Strains of H. pylori from subjects with peptic ulcer are more likely to
produce cytotoxin in vitro compared to those from subjects with non-ulcer dyspepsia
[Eaton et al., 1989; Figura et al., 1989; Cover et al., 1990], Antibodies to a 120 -
128 kDa protein were present in 100% of ulcer patients compared with about 70% of
infected controls [Crabtree et al., 1991]. The gene encoding this protein has been
cloned and called cytotoxin associated gene A (Cag A) [Tummuru et al., 1993].
Moleculer analysis of vacuolating cytotoxin A (vacA) from multiple strains indicates
that some regions are relatively conserved between groups of strains, whereas others
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are highly divergent [Cover et al., 1994; Atherton et al., 1995]. Two strikingly
divergent regions are the 50 base pairs encoding the second half of the signal
sequence and a 700 base pair region near the middle of the gene. All strains
examined possess one of two main types of signal sequence, si (which can be
subtyped into sla and sib) and s2, and one of two types of mid-region, ml or m2.
Strains classed as vacA sl/ml produce higher levels of vacuolating cytotoxin activity
in vitro than sl/m2 [Atherton et al., 1995]. Patients with peptic ulcer disease are
more likely to be infected with strains of the vacA si genotype than with strains of s2
genotype and those with the vacA si genotype are closely associated with cagA
positive status [Atherton et al., 1995].
1.5.6 Humoral responses
The immunoglobulin classes and subclasses of circulating and-//, pylori antibodies
are consistent with a prolonged chronic mucosal infection. IgG and IgA are
predominant and IgM antibodies rarely seen [Rathbone et al., 1986], Western
blotting of mucosal antibodies show that different patients have different patterns of
antibodies to the various antigens of H. pylori [Crabtree et al., 1991]. Mucosal
antibodies consistently detected a variety of surface antigens including the 28 kDa
subunits of urease and 61 kDa subunit of urease, 56 kDa heat shock protein, 54 kDa
flagellum protein and the 120 kDa and 87 kDa cytotoxin associated antigens [Newell
et al., 1994]. The 61 kDa protein is also reported to be a heat shock protein [Dunn et
al., 1992; Evans et al., 1992],
H. pylori infection leads to the development of gastric autoimmunity [Negrini et al.,
1991] which might contribute to the persistence of chronic inflammatory cells in the
gastric epithelium after eradication of H. pylori [Solcia et al., 1994], Binding of IgG
antibodies to H. pylori should promote complement dependent phagocytosis and
killing of bacteria by neutrophil polymorphs, this process occurs in vitro [Tosi and
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Czinn, 1990]; but H. pylori are resistant to phagocytosis by neutrophils which could
be due to an inhibitory effect of ammonium ions [Kist et al., 1993].
Mucosal IgA does not normally clear H. pylori infection. It might inhibit bacterial
functions, neutralise harmful bacterial products and diminish antigen uptake.
Patients with hypogammaglobulinaemia show what happens if humoral responses
are lacking. These individuals rapidly develop gastric atrophy and are 50 times more
likely to develop gastric cancer [Hermaszewski and Webster, 1993]. Gastric atrophy
in these cases may be due to excessive antigen uptake in the absence of mucosal
antibodies [Crabtree and Wyatt, 1993].
1.5.7 Cytokines and cell mediated responses
Electron microscopy of the mucosal cells shows damage to the plasma membrane,
vacuolation of the cytoplasm and ingested bacteria [Wyle et al., 1990], These cells
also show some features of activated macrophages in that they express HLA antigens
[Wee et al., 1992] which present antigens to CD receptors on lymphocytes [Crabtree
et al., 1994], A number of inflammatory mediators have been shown to be
increased in H. pylori infection: interleukin-1 (IL-1); interleukin-6 (IL-6);
interleukin-8 (IL-8) [Crabtree et al., 1991; Crabtree et al., 1993; Noach et al., 1994];
tumour necrosis factor-a (TNF-a) [Crabtree et al., 1991]; interferon-y [Fan et al.,
1993]; and platelet activating factor (PAF) [Denizot et al., 1990]. H. pylori induces
gastric epithelial cells to increase expression of IL-8 which attracts neutrophil
polymorphs and induces these and mononuclear cells to express cytokines including
IL-8 itself [Crabtree et al., 1993].
H. pylori also induces blood monocytes and polymorphs to release reactive oxygen
species in vitro [Neilsen and Andersen, 1992] and in the gastric and duodenal
mucosa of infected patients [Davies et al., 1994], Reactive oxygen species have a
detrimental effect on the viscoelastic properties of gastric mucus [Grisham et al.,
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1987] and can also cause tissue damage. Host tissues are normally protected against
oxidative damage by antioxidant substances such as ascorbic acid. Ascorbic acid
also diminishes the oxidative generation of harmful substances such as N-nitroso
compounds [Mirvish, 1994], H. pylori gastritis decreases the amount of ascorbic
acid in gastric juice, which could increase the susceptibility of the mucosa to
oxidative damage. Gastric juice ascorbate levels rise after eradication of H. pylori
[Sobala et al., 1993]. Free oxygen radicals have been implicated in carcinogenesis
in other organs [Feig et al., 1994].
1.5.8 Density ofH. pylori colonization
H. pylori density is associated with cagA and vacA genotype; strains with these two
genes colonise the mucosa more densely than cagA and vacA negative strains.
Atherton and colleagues found a strong association between antral bacterial density
and duodenal ulcer disease [Atherton et al., 1996]. Alternatively, more dense
infections associated with more antral inflammation and epithelial damage, might
cause lower somatostatin expression [El-Omar et al., 1995], contributing to the
higher levels of gastrin and acid production [Kaneko et al., 1992] which might
predispose to duodenal ulceration.
1.5.9 Glycoconjugates on the Lipopolysaccharide of H. pylori
H. pylori LPS has low endotoxic activity, induces a low immunological response,
and has been implicated in a variety of biological interactions [Moran, 1995]. These
include: an inhibitory effect on mucus glycosylation; interference with mucosal
integrity; inhibition of the interaction of mucin with its receptor [Pilotrowski et al.,
1993]; the stimulation of pepsinogen secretion; and a role in the mediation of
adherence of the bacterium to laminin in the basement membrane [Valkonen et al.,
1994].
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The O-antigen regions of the LPS purified from H. pylori contain partially
fucosylated N-acetyllactosaminoglycan chains terminated by a Lewis type 2
immunodetrminant, either Lewisx or LewisY [Aspinall and Monteiro, 1996; Aspinall
et al., 1996]. Immunoelectron microscopy and ELISA were used to demonstrate
presence of Lex in LPS but Lea or Le^ were not identified by these methods
[Sherburne and Taylor, 1995]. The expression of Lex epitopes on the surface of the
bacterium may play a role in the development of an autoimmune reaction against
host cells expressing similar antigens which might contribute to disease [Aspinall et
al, 1996]
1.6 H. pylori associated disease
H. pylori infection is almost always associated with inflammation; however, peptic
ulcer disease and gastric carcinoma occur in only a subset of individuals infected
chronically with H. pylori. There is now mounting evidence that H. pylori plays a
major etiological role in peptic ulcers and there are two different patterns of gastritis,
one associated with duodenal ulceration and the other with gastric ulceration .
I.6.1 H. pylori and gastritis
It is now well established that H. pylori is the main etiological agent underlying
chronic gastritis. Evidence to support this comes from both human and animal
studies as well as therapeutic trials. Marshall ingested a culture of H. pylori and
within seven days developed acute gastritis in which the organisms were identified
in the biopsy [Marshall et al., 1985], A similar second experiment on a volunteer
produced a picture of chronic gastritis in which hypochlorhydria continued for some
weeks [Sobala et al., 1991] . In 1984 Marshall and colleagues isolated C. pylori (H.
pylori ) from biopsy specimens taken from consenting patients presenting for
gastroscopy. The bacteria were present in almost all patients with active chronic
gastritis, duodenal ulcer, or gastric ulcer. They found a close association between
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H. pylori and antral gastritis [Marshall and Warren, 1984]. In addition, the
therapeutic trials in which patients with gastritis were treated with either placebo or a
combination of nitrofuran and amoxycillin showed that simultaneous clearance of H.
pylori and improvement of gastric histology was seen only in those patients treated
with antibiotics [Moss and Calam, 1992],
I.6.2 H. pylori and duodenal ulcer
H. pylori infection is associated world-wide with duodenal ulcers; the infection was
diagnosed in 94% of 1695 duodenal ulcer patients [reviewed by Kuipers et al.,
1995]. Duodenal ulceration is associated with chronic duodenitis, an observation
supported by one study in which 82% of 219 patients followed up for symptomatic
duodenitis developed one or more duodenal ulcers [Sircus, 1985]. A long term
follow up study has shown that subjects with antral gastritis are 14 times more likely
to develop a peptic ulcer than those with normal gastric mucosa [Sipponen et al.,
1990], A common histological finding in chronic duodenitis is surface gastric
metaplasia. It is thought to be a consequence of hyperacidity and independent of
duodenitis or H. pylori colonization, but H. pylori can be detected in the duodenum
only in the presence of gastric metaplasia and not in normal tissue [Steer, 1984;
Johnston et al., 1988].
Therapeutic evidence has supported a role for H. pylori in duodenal ulceration.
Before H. pylori was formally identified, it was reported that remission periods in
patients with duodenal ulcer were prolonged following tripotassium
dicitratobismuthate (bismuth chelate) which is active against H. pylori, rather than
an H2 antagonist alone. There is now a wealth of information showing that the
relapse rate of duodenal ulceration is reduced by eradication of H. pylori [Moss and
Calam, 1992]. The most important evidence linking H. pylori and ulcer disease is
the finding that successful eradication of H. pylori speeds up ulcer healing [Marshall
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et al., 1988; Labenz and Borsch, 1994], prevents duodenal and gastric ulcer relapse
and reduces ulcer complications. Clearly, H. pylori eradication has marked effect on
the natural history of peptic ulcer disease [reviewed by Rauws and Tytgat, 1995].
Eradication of H. pylori, defined as the inability to demonstrate the bacteria on
antral biopsy one month after the initial clearance of the organism with antibacterial
treatment, is associated with prolonged remission for healed duodenal ulcers
[Coghlan et al., 1987]
1.6.3 H. pylori and gastric ulcer
H. pylori infection was diagnosed in 86% of 1022 gastric ulcer patients [reviewed by
Kuipers et al., 1995]. The diagnosis of H. pylori infection in gastric ulcer patients is
more problematic than in duodenal ulcer patients. Gastric ulcer disease is associated
with a higher prevalence of atrophic gastritis, intestinal metaplasia and with a lower
acid output. These conditions lead to a more diffuse spread of the bacteria
throughout the stomach and to the lowering of colonization densities particularly in
the antrum [Fiocca et al., 1992; Louw et al., 1993]. This increases the risk of false-
negative results from biopsy. A study of 36 patients with atrophic gastritis found H.
pylori in biopsy specimens from only 33%, but 86% had serological evidence of
infection [Karnes et al., 1991]. Other studies suggest that eradication of H. pylori
reduces the relapse rate as well as enhances healing in patients with gastric ulcers
[Graham et al., 1992]
Gastric ulcers also result from use of non-steroidal anti-inflammatory drugs
(NSAIDs). The prevalence of gastric erosions in patients on long term NSAID
therapy is about 50%, but the prevalence of gastric ulcers is at least 15% [Larkai et
al., 1987; Silvos et al., 1979]. The prevalence of H. pylori infection in patients
taking NSAID has been reported to range from 22% to 63% [Loeb et al., 1990;
Maxton et al., 1990]. Histological evidence of gastritis in patients taking NSAID is
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related to H. pylori infection rather than use of NSAID [Shallcross et al., 1990;
Laine et al., 1991].
1.6.4 H. pylori and gastric cancer
Between 60 and 100% of subjects with gastric adenocarcinoma are infected with H.
pylori at diagnosis. It has been postulated that type B gastritis due to H. pylori leads
to intestinal metaplasia, atrophic gastritis, achlorhydria and finally gastric cancer. H.
pylori infection has been reported in 44-97% of subjects with atrophic gastritis, 59 -
93% with intestinal metaplasia and 87 - 100% with dysplasia [reviewed by Lambert
et al., 1995].
Dooley [1991] reported that H. pylori might not cause gastric carcinoma but gastritis
induced by this organism could act as the productive soil upon which other
environmental variables act. Forman et al. [1990; 1991] found that antibodies to the
organism are present in the majority of gastric cancer patients. Geographic studies
of gastric cancer and H. pylori reveal close epidemiological parallels between the
two [ Parsonnet, 1993] (Table 1.2).
In animal models of gastric carcinogenesis, H. pylori infection appears to predispose
to the development of gastric cancer [Fox, 1994]. As non-infected individuals never
develop carcinoma, the relationship between H. pylori and different steps in
carcinogenesis requires further investigation.
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Table 1.2 Prevalence of H. pylori infection (% +ve) among patients with gastric







































1.7 Diagnosis ofH. pylori infection
The diagnosis of H. pylori infection like any other bacterial infection, involves
identifying the bacterium by microscopy, culture, serology and/or specific DNA
testing and detection of inflammation. Detection methods for H. pylori can be
categorised as direct or indirect. Histologic demonstration of the organism or its
identification by microbiological means from cultured tissue constitute direct
evidence of its presence. Indirect techniques rely on detecting a characteristic of the
bacteria such as hydrolysis of urea or the response of the immune system to its
presence (specific antibodies).
1.7.1 Direct methods based on gastric biopsies
H. pylori is almost always found in the antral region where it induces inflammation,
in the fundus and sometimes in the duodenal bulb. At endoscopy the tissue sample
should be taken from the antral region at approximately 2 cm from the pylorus.
Sampling errors can be minimised by taking two antral biopsies and by obtaining an
additional biopsy from the body or from the fundus of the stomach. The experience
of several investigators indicates that two biopsy samples will substantially increase
the sensitivity [Hazell et al., 1987; Goodwin and Armstrong, 1990], Some authors
have recommended brushing the gastric surface rather than taking biopsies in order
to study a larger area [Debongnie et al., 1992],
I.7.1.1 Histological examination
For histological examination, biopsies should immediately be put into a fixative such
as formaldehyde or Bouin's solution. The particular morphology and location of H.
pylori facilitate diagnosis by microscopy. It can be identified with a standard
haematoxylin and eosin stain; the bacteria appear rose coloured [Taylor et al., 1987].
The Giemsa stain is a more consistent and less costly alternative [Gray et al., 1986].
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Other stains that have been proposed for H. pylori diagnosis include Brown-Hopps
[Westblom et al., 1988], cresyl fast violet [Burnett et al., 1987], histological half-
Gram [Trowell et al., 1987; Britt et al., 1990], carbol fuchsin [Rocha et al., 1989]
and modified Wright's stain [Butler, 1990]. Excellent results were obtained with the
Warthin Starry stain, a technique in which the bacteria stain black on a yellow
background, but the technique is time consuming [Warren, 1983].
1.7.1.2 Rapid urease test
Urease catalyses urea to ammonia and bicarbonate. This reaction causes an increase
in the pH of the surrounding medium, which can be detected with a pH indicator and
the presence of urease is signalled by a colour change. The first urease test
described for detection of H. pylori employed Christensen's 2% urea broth, a
standard microbiologic reagent used to identify urease producers [McNulty and
Wise, 1985]. The great advantage of this test is that it can be performed in the
endoscopy room as soon as the biopsy has been taken. The Campylobacter - like
organism (CLO) test is the most widely employed commercially available
modification of the urea broth with the same phenol red indicator as Chistensen's
urea broth [ Marshall et al., 1987]. The biopsy is placed on a special agar which has
been brought to room temperature. A colour change from yellow to red is recorded
after 30 min and 2 hours. The sensitivity of this test is in the range of 90 to 95%
[Borromeo et al., 1987; Bomschein et al., 1989].
1.7.1.3 Bacteriological examination
Biopsies for culture should be maintained at 4°C in a container with saline solution
to avoid drying. H. pylori culture suspensions in distilled water and physiologic
saline have been shown to remain viable for days at 7°C, but the organism rapidly
loses viability at room temperature [Hartmann et al., 1987; West and Millar, 1990].
If the delay between biopsy and testing is longer than 4 hours, a transport medium
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such as 20% glucose solution [Goodwin et al., 1985], thioglycolate broth, nutrient
broth, Brucella broth [Coghlan et al., 1987], Stuart's transport medium [Faoagali et
al., 1986] or Portagerm pylori (bioMerieux) should be used. In Gram stains of
smears prepared by rubbing a biopsy specimen on a glass slide, the spiral and curved
bacteria appear Gram negative and are usually found in large numbers in different
zones of the slide. This is a quick, simple and inexpensive test with a sensitivity
about 80% [Montgomery et al., 1987].
Biopsy suspension or biopsy specimens are inoculated on to two fresh plates; the
first non-selective medium such as 10% blood agar, and a second selective medium
[Tee et al., 1991]. Skirrow's medium which contains vancomycin, trimethroprim
and amphotericin B has been used by many workers to isolate H. pylori. Isolation
rates are higher for selective medium compared with non-selective media [Leunk et
al., 1988], Goodwin and colleagues have used nalidixic acid with vancomycin and
amphotericin B as selective agents [Goodwin et al., 1985]; however, 14% of the
strains are sensitive to nalidixic acid and 5% of strains are sensitive to polymyxin B
or colistin [Dent and McNulty, 1988]. An alternative agent which inhibits
pseudomonads and other bacteria flora is Dent's formula (vancomycin, cefsulodin,
trimethroprim and amphotericin B) [Dent and McNulty, 1988],
The plates are incubated for 3 to 7 days at 37°C in a microaerophilic atmosphere.
The colonies are identified by gross morphology and biochemical characteristics
such as urease, oxidase, catalase and y-glutamyl transpeptidase [Megraud et al.,
1985],
1.7.1.4 Polymerase chain reaction (PCR)
PCR has the potential for diagnosing infection even when the target organism is in a
non-culturable state or no longer alive. The first reports of the use of PCR for
diagnosis of H. pylori infection used primers that amplified a fragment of the
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bacterial ribosomal 16S gene [Hoshina et al., 1990; Engstrand et al., 1991]. Other
investigators have used primers based on the urease gene [Valentine et al., 1991;
Clayton et al., 1992], The choice of the urease gene as a target for amplification
assures that all urease negative organism are unlikely to interfere with detection of
H. pylori. To evaluate gastric biopsy specimens, Hammar and colleagues used
sequences of primers corresponding to the H. pylori gene encoding a 26 kDa antigen
that appears to be species specific [Hammar et al., 1992].
I.7.2 Indirect methods
1.7.2.1 Serology
H. pylori is not an invasive bacterium, but it actively stimulates the immune system
of its host by release of lipopolysaccharides and immunogenic proteins. An immune
response accompanies the presence of the bacterium in 98% of cases [Glupczynski et
al., 1992], Among patients with H. pylori present in gastric biopsy, antibody titres
to pooled H. pylori whole cell antigen are higher for IgG and IgA than among biopsy
negative patients. IgM antibodies do not appear to differ between H. pylori negative
and positive individuals [Rathbone et al., 1986]. ELISA has been found to be more
sensitive in detection of H. pylori antibody than bacterial agglutination or
complement fixation [Jones et al., 1986]. Many companies have developed
commercial kits using purified antigen. Quick tests have also been developed based
either on ELISA (Flexisure, Helisal, Immunocomb, Quick vue) or agglutination
(Pylori set dry, H. pylori Kit). The ELISA tests available are generally satisfactory
with regard to sensitivity and specificity. IgG does not usually appear until several
weeks after infection, and after eradication, decreases in the titre are not significant
until the 6th month [Kosunen et al., 1992],
1.7.2.2 Urea breath test
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A breath test based on H. pylori's, efficient hydrolysis of urea is the labelled carbon
breath test. In infected individuals, the urea is metabolised to ammonia and labelled
bicarbonate, and excreted in the breath as labelled carbon dioxide. The labelled
carbon excreted can then be quantified. The original description of this technique
used the stable, naturally occurring isotope [ Graham et al., 1987]. There are
also commercial kits available (BSIA, Inbiomed). Another breath test using *4^
has been devised [Debongnie et al., 1991; Henze et al., 1990; Marshall and
Surveyor, 1988]. can be easily quantified but it cannot be used in some
countries for legal reasons.
1.8 Treatment ofH. pylori infection
1.8.1 Antimicrobial agents
There are many treatment regimens available but their efficacy varies from centre to
centre and from country to country. H. pylori is a bacterial infection, so an
antimicrobial agent seems a logical therapeutic choice. H. pylori is sensitive to a
large number of antimicrobials in vitro but not in vivo. The failure of antimicrobials
to act in vivo include the preferred site of the bacteria buried deep in gastric pits
protected by the mucous layer as well as the acid milieu of the stomach interfering
with the drug's ability to destroy H. pylori.
Triple therapy with bismuth, metronidazole and tetracycline or substituting
amoxycillin for tetracycline results in the best eradication rate with the lowest degree
of variability [Tytgat and Noach, 1994]. Regimens including bismuth are the most
effective and the most consistently reproducible. The more compliant the patients
the more effective is the treatment. Resistance to metronidazole can be a limiting
factor but is not a contraindication to triple therapy. Seven days of tetracycline and
metronidazole appears to be efficient [Johnston et al., 1993]; longer periods, whilst
resulting in more side effects, seem to allow resistant strains to be eliminated
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[Burette et al., 1992], In a study of 100 patients treated with bismuth, tetracycline
and metronidazole for 15 days, eradication rates of 93% were achieved and less than
3% had significant side effects requiring the medication to be terminated [Thijs et
al., 1993],
1.8.2 proton-pump inhibitors
The proton-pump inhibitor omeprazole has also been proposed as a suitable addition
to H. pylori treatment. Omeprazole directly suppresses but does not eradicate H.
pylori infection unless combined with an antibiotic such as amoxycillin
[Bayerdorffer et al., 1993]. The combination of omeprazole and amoxycillin showed
promise in achieving H. pylori eradication [Unge et al., 1989]. The proton-pump
inhibitors omeprazole, lansoprazole and pantoprazole all have intrinsic in vitro
antimicrobial activity, but suppression rather than eradication is observed with each
[Iwahi et al., 1991; Suerbaum et al., 1992], Omeprazole, tetracycline and
metronidazole achieved an eradication rate of 98% [McCarthy et al., 1993], Rates
approaching 98% have been achieved with omeprazole, clarithromycin and
amoxycillin. Use of these antibiotics for only 1 week have achieved rates over 90%
[Logan et al., 1994],
1.8.3 Sucralfate
Sucralfate, an aluminium salt of sucrose octasulphate, is a clinically effective drug
for the prevention of acute gastric mucosal lesions induced by a topical irritant such
as ethanol [Tarnawski et al., 1987] or aspirin [Konturek et al., 1986] and for the
prophylaxis and therapy of peptic ulcer [Koeltz and Halter, 1989; Marks et al.,
1989]. Sucralfate reduced H. pylori density and improved chronic antral gastritis
associated with duodenal ulcer [Hui et al., 1989].
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Slomiany and colleagues reported that both components of sucralfate, sucrose-
octasulphate and aluminium, inhibit both H. pylori adhesion to the gastric mucosal
surface and H. pylori growth [Slomiany et al., 1992]. Sucralfate alone for 4 weeks
and sucralfate with amoxycillin for 2 weeks cleared H. pylori in 17% and 47%
respectively and eradication 4 weeks after ending treatment in 0% and 40% of
patients respectively. Thus sucralfate alone suppresses but does not eradicate H.
pylori infection [Hu et al., 1993]. Sucralfate combined with either amoxycillin and
metronidazole or tetracycline and metronidazole produced high eradication rates
[Wurzer et al., 1994].
1.9 Blood group antigens and susceptibility to infectious agents
1.9.1 ABO Blood groups
The ABO blood group system was first described by Landsteiner and colleagues
early in this century. Their work demonstrated that individuals could be segregated
into distinct groups based on the presence or absence of substances in serum that
could agglutinate erythrocytes isolated from individuals of other groups. This work
quickly found practical application in blood transfusion and modification of the
original agglutinating methods are still in use in pretransfusion blood typing and
cross matching [Mollison et al., 1987; Walker, 1990; Rossie et al., 1991], Four
major blood group were identified (Table 1.3). The ABO and Lewis blood group
antigens are found not only on red cells but can be found in many secretions and on
numerous cells of the human body (Table 1.4). The antigenic structures that
characterise the ABO blood group are widely distributed in many animals, some
plants and many bacteria. Springer [1970] demonstrated that Gram-negative bacteria
express substances which are similar to the A, B and H (the antigen of blood group
O) antigens of human.
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Table 1.3 Antigens and isohaemagglutinins of the ABO blood group system
Group Antigens on red cells Antibodies in serum
A A, H Anti-B
B B, H Anti-A
AB A, B, H None
O H Anti-A and Anti-B
H is the blood group O antigen and also present on the cells of other blood groups.
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Table 1.4 Distribution of ABO and Lewis blood group antigens on cells and in body
fluids of secretors and non-secretors
Secretors H, A or B Lea Leb
Secretions + -/+ +
Cells + -/+ +
Non-secretors
Secretions - + -
Cells + + -
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1.9.2 Epidemiological studies on infectious diseases
The associations between ABO blood groups and secretor status with susceptibility
to infectious disease were collected and analysed by Mourant et al. [1978] and more
recently by Blackwell and colleagues [Blackwell et al., 1989]. Table 1.5
summarises the associations of infectious diseases and ABO blood groups. The
secretor status is based on detection of the water soluble glycoprotein form of ABO
antigens in body fluids (secretors). These are absent in a minority of individuals in
most populations (20 - 25%) (non-secretors). Epidemiological studies demonstrated
increased susceptibility for non-secretors of ABH blood group antigen to many
diseases due to bacteria or yeasts or asymptomatic carriage of some species. Studies
of viral diseases indicated that secretors were over represented among these patients
(Table 1.6).
1.9.3 Secretor status and Lewis blood group antigens
In 1946, Mourant found an antibody in the serum of Mrs HDG Lewis which
agglutinated red cells of approximately 20% of normal blood group donors. The
antigen was initially referred to as Lewis and later Lewisa or Lea [Mourant, 1946],
Two years later Andresen described an antigen thought to be coded by an allele of
Lea that was called Lewis*5 or Le*5 [Andresen, 1948], It was shown that all donors
with Lea positive red cells were non-secretors of ABH antigen and all donors with
Le*5 positive red cells were secretors of their ABH antigens in saliva [Grubb, 1948].
The predicted proportion of these two phenotypes within a population is secretors 75
- 80% and non-secretors 20 - 25%. This ratio can vary widely in different ethnic
groups and some geographically isolated populations [Mourant et al., 1976].
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Table 1.5 Associations between infectious diseases and ABO blood groups


































Burford-Mason et al., 1988
Aly etal., 1991; 1992
Pradhan et al., 1971
Socha etal., 1969
Robbinson etal., 1971
Barua and Paguio, 1977
Aird et al., 1953
Socha etal., 1969
Kinane et al., 1982
Foster and Labrum, 1976
Gupta and Chowdhuri, 1980
Table reproduced and modified from Blackwell (1989)
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Table 1.6 Associations between infectious diseases and secretor status
Infection agent and disease Secretor status References
Oral cavity
C. albicans disease Non-secretors Aly etal., 1991
C. albicans carriage Non-secretors Aly et al., 1992
Caries Non-secretors Holbrook and Blackwell, 1989
Respiratory tract
Strep, pyogenes (group A) Non-secretors Haverkorn and Goslings, 1969
Strep, pneumoniae Non-secretors Blackwell et al., 1986
Neisseria meningitidis Non-secretors Blackwell etal., 1986
H. influenzae (type b) Non-secretors Blackwell et al., 1986
Echo virus Secretors Raza et al., 1991
Influenza A and B Secretors Raza et al., 1991
Respiratory Syncytial Virus Secretors Raza et al., 1991
Rhinovirus Secretors Raza et al., 1991
Gastrointestinal tract
Vibrio cholerae Non-secretors Chaudhuri and Adhikary 1978
Peptic ulcers Non-secretors Clarke et al., 1956
Genitourinary tract
HIV (heterosexual transmission) Secretors Blackwell etal., 1991
Table reproduced and modified from Blackwell (1989)
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The Le gene has been cloned and codes for an a 1,3/4 fucosyltransferase that is
expressed in exocrine secretions and transfers fucose to the subterminal (3GlcNAc
unit of precursor chains [Kukowska et al., 1990; Prieels et al., 1981 ] (Figure 1.1).
The secretor gene has been cloned and codes for an a 1,2 fucosyltransferase that
transfers fucose to the terminal |3Gal unit of precursor chains. The secretor
fucosyltransferase is expressed in salivary glands, where its presence is correlated
with the presence of ABH blood group substances in saliva [reviewed by Henry et
al, 1995],
Lea and Le^ antigens do not form part of the structure of the cell membrane and are
not synthesised on the red cells but are present in the plasma and in the body fluids.
In secretions, the Lewis determinants are carried on the same glycoprotein molecules
as the ABH antigens [Watkins, 1974].
1.9.4 Structures of the ABH antigens
The ABH blood group molecules are synthesised by the sequential action of
enzymes termed glycosyltransferases [Watkins, 1980; Lowe, 1991]. Each enzyme is
encoded by a distinct genetic locus and catalyses the addition of a specific
monosaccharides to a specific position on the oligosaccharide precursor, or acceptor
molecule [Dawson, 1978], Some transferases such as that coded for by the Le gene,
can transfer the same monosaccharides to several different acceptors leading to the
formation of Lea or Le^.
1.9.4.1 Precursor chains
A, B and H substances are found mainly in the cell membranes as glycolipids, and
mainly in secretions as glycoproteins. There are 4 major types of these precursor
molecules to which different monosaccharides are added by glycosyltransferases to
produce the A, B and H antigens. Type 1 and type 2 precursors are, in turn, found
41
covalently attached to some proteins by linkage to asparagine residues ( asparagine-
linked oligosaccharides) and also found attached to membrane associated lipid
molecules (Figure 1.1). Type 1 chains are found mainly in the secretions and type 2
chains are found on the red cells and on most other cells of the body except the brain
[Oriol et al., 1986], Type 3 and Type 4 precursor chains have been identified but not
studied extensively as type 1 and type 2 [Takasaki et al., 1978; Donald, 1981] and
their biosynthetic regulation and distribution is not yet fully understood [Clausen et
al., 1986]
1.9.4.2 ABH antigens
ABH precursor oligosaccharides are modified by the action of a(l,2)
fucosyltransferases. These enzymes catalyse a transglycosylation reaction in which
fucose is transferred from the substrate GDP-fucose to the second carbon atom of the
galactose displayed at the non-reducing terminus of the oligosaccharide precursor
(Figure 1.2). The disaccharide unit formed in this manner, Fuca(l,2)Gal(3-,
represents the H blood group [reviewed in Watkins, 1980]. The H gene codes for
production of a fucosyltransferse enzyme which adds L-fucose to the C2 position of
the terminal sugar residue of Type 2 chains to form H Type 2. The A allele at the
ABO locus encodes an a l,3N-acetylgalactosaminyl transferase that utilises H
molecules to form the blood group A molecule, whereas the B allele encodes an a 1,3
galactosyltransferase that forms blood group B determinants. The O allele is a null
allele that does not encode a polypeptides capable of modifying H active precursors
[reviewed in Watkins, 1980] (Figure 1.2).
The Type 1 precursor chain is fucosylated by the product of the Se gene, an a 1-2
fucosyltransferase to form H Type 1 [Watkins et al., 1988]. H Type 1 acts as a
substrate for A or B glycosyltransferases to give rise to their respective antigens.
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Type 1 Gal|31 3GlcNAc(3 R (Protein chain)
Type 2 Gaipi 4GlcNAc(3 R (Lipid chain)
Type 3 Gal(3l 3GalNAca R (Serines or threonines)




Figure 1.1 Main precursor types of ABH active oligosaccharide
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Figure 1.2 Production of A, B and H (0) antigens from precursor Type 1 and 2
chains. The blood group A transferase requires UDP-N-acetylgalactosamine as its
sugar nucleotide substrate, whereas the blood group B transferase requires UDP-
galactose. Type 3 and 4 A, B and H determinants are synthesized in an identical
manner.
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1.9.5 Interaction of the products of the A, B, H, Se and Le genes
Although there are two antigens, Lea and Le®, there is only one Le gene, which
encodes an al-3/4 fucosyltransferase. The Lea antigens are the a(l-4)
monofucosylated type 1 chain and Leb antigens are a(l-2) and a(l-4) difucosylated
type 1 chain [reviewed by Oriol et al., 1986]. The enzyme coded by the secretor
gene adds fucose to the terminal sugar of the type 1 precursor and that coded for by
the Lewis gene adds fucose to the subterminal sugar of the type 1 precursor. If the
secretor enzyme adds fucose first, the structure can act as a substrate for the Lewis
enzyme to form Leb antigen. If the Lewis enzyme adds fucose to the subterminal
sugar first to form Lea, the secretor gene can not use the Lea as a substrate to form
Leb [Watkins et al., 1988]. The presence of Lewis antigens in secretions and on cell
surfaces depends on the expression of the Le gene and not on the Se gene.
Individuals who do not express any Lewis determinants on their red blood cells or in



















Q Fucose 0 N-acetyl-D-glucosamine
O N-acetyl-D-galactosamine ■ Galactose
Figure 1.3 Production of H, A, B and Lewis antigens from precursor type 1
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1.9.6 Blood group antigens act as receptors for microorganisms
There is evidence that blood group antigens can act as receptors for some
microorganisms and this might explain some of the association reported between
blood group and disease [Mourant et al., 1978]. Table 1.7 summarises the blood
group antigens that act as receptors for microorganisms [Blackwell, 1989]. The
Duffy antigen has been demonstrated in vitro to be a receptor for Plasmodium
knowlesi which is closely related to P. vivax [Miller et al., 1975]. This antigen is
expressed in white populations but is absent in the majority of African and American
Blacks [Sanger et al., 1955] and this might explain why African Blacks are more
resistant to malaria infection caused by P. vivax [Miller et al., 1975], P blood group
was reported to be the receptor for fimbrial adhesins expressed on strains of E. coli
[Kallenius et al., 1980], L-Fucose containing glycoconjugates are proposed as
epithelial receptor for Candida albicans on the basis of adhesion inhibition studies
using sugars and lectins as blocking agents [Critchley and Douglas, 1987]. Lea, H
type 1 and H type 2 blood group antigens have been proposed as possible epithelial
cell receptors for C. albicans [May et al., 1989; Brassart et al., 1991; Tosh and
Douglas, 1991; Cameron and Douglas, 1996]. The Le^ blood group antigen has
been reported to mediate H. pylori attachment to human gastric mucosa. Soluble
glycoprotein presenting the Le^ antigens or treatment of cells with antibodies to the
Le^ antigens were shown to inhibit bacterial binding [Boren et al., 1993].
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Table 1.7 Blood group antigens that act as receptors for microorganisms
Microorganisms blood group receptors References
C. albicans Lea May et al., 1989
C. albicans H type 2 Tosh and Douglas, 1992
H. pylori Leb Boren et al., 1993
E. coli P Kallenius et al., 1980
M Vaisanen et al., 1982
N Jann et al., 1988
S Korhonen et al., 1986
H. influenae type B Anton Van alphen et al., 1986
S. aureus Lea Saadi et al., 1993
Plasmodium knowlesi Duffy Miller et al., 1975
Table reproduced from Blackwell (1989) with modifications
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The increased proportion of non-secretors among carriers of some potentially
pathogenic bacteria and yeasts might be attributed to the Lea antigen acting as one of
the host cell receptors for some organisms [Blackwell, 1989; May et al., 1989;
Rahat, 1990, Tosh and Douglas, 1991; Aly, 1992; Saadi et al., 1993]. Saadi and
colleagues [1993] found binding of S. aureus to buccal cells correlated with the
amount of monoclonal anti-Lea bound to the cells. Pretreatment of cells with
monoclonal anti-Lea or anti-precursor type 1 antibodies significantly reduced
bacterial binding [Saadi et al., 1993]. Alternatively, if the terminal fucose of H type
2 is an important receptor for adhesins of some microorganisms, the terminal fucose
of Leb in mucosal secretions might bind to these adhesins and reduce colonisation.
1.10 Aims of the study and hypothesis to be tested
Blood group O and non-secretion were strongly associated with peptic ulcers.
Clarke and colleagues in 1955 and 1956 demonstrated that when duodenal and
gastric ulcers were classified separately, the association was more strongly
associated with group O individuals and non-secretors [reviewed by Mourant et al.
1978]. H type 2, the antigen of blood group O, is found on the cells of all
individuals except the very rare Bombay phenotype [reviewed by Race and Sanger,
1975]. The studies of Boren and colleagues indicated that Le^ is the receptor for H.
pylori on mucosal surfaces. As non-secretors do not express this antigen, this
hypothesis could not explain the reported increased susceptibility of non-secretors to
peptic ulcers. The work presented in this thesis involved three areas of
investigations: 1) a clinical survey to assess genetic and environmental factors
associated with isolation of H. pylori from patients undergoing gastroscopy; 2)
laboratory studies of genetic and environmental factors influencing binding of H.
pylori to epithelial cells, and 3) the effect of ABO blood group on inflammatory
responses.
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The objectives of the study were:
1 - to assess blood group and secretor status of local patients with peptic ulcer
disease;
2 - to determine if H. pylori binds to blood group antigens and if environmental
factors such as fasting or smoking affect the binding;
3 - to isolate bacterial adhesins that bind to the blood group antigens by the method
used for the S. aureus adhesin that binds Lea;
4 - to determine if there are differences in the immune or inflammatory responses to
H. pylori associated with ABO blood group or secretor status.
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Chapter 2 General Materials and Methods
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All chemicals were analytical grade obtained from BDH Chemicals Ltd. UK or
Sigma UK.
2.1 Buffers and solutions used for enzyme linked immunosorbent
assays (ELISA)
2.1.1 Coating buffer (carbonate-bicarbonate buffer)
Coating buffer consisted of sodium carbonate (15 mM), sodium bicarbonate (35
mM) and sodium azide (3 mM) (pH 9.6).
2.1.2 Phosphate buffered saline (PBS)
PBS contained sodium chloride (15 mM), sodium orthophosphate (3.7 mM) and
disodium hydrogen phosphate (9. 6 mM) (pH 7.2).
2.1.3 Washing buffer
Washing buffer consisted of (0.1 % w/v) bovine serum albumin (BSA) and (0.05 %
v/v) Tween-20 in PBS (pH 7.2).
2.1.4 Blocking buffer
Blocking buffer was prepared by adding BSA (1 % w/v) to PBS.
2.1.5 Phosphate citrate buffer
Phosphate citrate buffer contained sodium hydrogen phosphate (0.1 M) and citric
acid (0.1 M) (pH 5).
2.1.6 Substrate solution
The substrate solution used to detect horseradish peroxidase (HRP) labelled
antibodies contained 40 |ig O-phenylenediamine in 100 ml of 0.1 M phosphate
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citrate buffer (pH 5.0) activated immediately before use by adding 40 pi H2O2
(30% v/v).
2.1.7 Stopping solution
The stopping solution contained of 12.5 % (v/v) H2SO4.
2.2 Gastric adenocarcinoma cell line (Kato III)
Kato III cells were received in ampoules from the European Collection of Animal
Cell Cultures. RPMI medium (1 ml) ( 500 ml RPMI, 5% foetal calf serum, 1%
glutamine and 1% penicillin/streptomycin) was added to the ampoule. The cells
were transferred to a universal container, 25 ml of medium was added and the tube
centrifuged for 10 min at 300 x g. Cells were resuspended in 25 ml RPMI in a
growth flask and incubated overnight at 37 °C in 5% C02. The cells were collected
by scraping the flask with a cell scraper and washed twice in PBS by centrifugation
at 300 x g for 10 min. The concentration was adjusted by determination of the total
number of cells microscopically with a Neubauer counting chamber.
2.3 Determination of ABO and Lewis blood groups
Blood samples were collected from patients and placed in plain tubes without anti¬
coagulant. The serum was separated and stored at -20°C. The ABO blood group of
the patients was determined from blood specimens by slide agglutination with
monoclonal anti-A and anti-B (Scottish National Blood Transfusion Service). Tube
agglutination with anti-Lewisa (Lea) and anti-Lewis^ (Le^) (Scottish National Blood
Transfusion Service) was used to assess Lewis group for secretor status. Non-
secretors cannot express Le^, therefore patients whose cells were agglutinated by
anti-Lea only were classed as non-secretors and those agglutinated by anti-Le^ as
secretors.
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2.4 Purification of monoclonal anti-Lea and anti-Le^
Synsorb affinity adsorbent (Chembiochem Ltd., Edmonton, Canada) with the
synthetic carbohydrate determinant of Lea or Le^ covalently linked to the silica
matrix was used to purify the anti-Lea and anti-Le^ monoclonal antibodies. Mouse
hybridoma culture supernatant (20 ml) containing anti-Lea antibody (LM 112/161)
or anti-Le^ (LM 112/81) antibody was kindly provided by Dr. R. Fraser, Scottish
Antibody Production Unit (SAPU) Glasgow and West Scotland Blood Transfusion
Service, Law Hospital, Carluke, Lanarkshire, UK. The supernates were mixed with
lg of the corresponding Synsorb beads overnight at 4°C. The unbound antibodies
were removed by centrifugation at 50 x g for 10 min and the beads were washed
twice with PBS by centrifugation at 50 x g for 5 min. The bound material was eluted
by adding 5 ml of 2% (v/v) ammonia (BDH, 35%) in saline (pH 11) to the beads for
15 min at room temperature followed by centrifugation at 50 x g for 5 min. The
supernatant was dialysed against PBS overnight and stored at -20°C. The washed
beads were stored in ethanol ( 70 % v/v) at 4°C.
2.5 Monoclonal and polyclonal antibodies
Monoclonal and polyclonal antibodies, the animal from which they were obtained,
isotype and source are listed in Table 2.1
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Anti-Lea (red cell typing)




























* FITC fluorescein isothiocyanate labelled
+ HRP = horseradish peoxidase labelled
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2.6 Bacteria
H. pylori, strains NCTC 11637 and NCTC 11916 were obtained from the Central
Public Health Laboratory (Colindale) and 51 isolates were isolated from
endoscopic biopsies of patients attending the gastroscopy clinic at the Western
General Hospital.
2.6.1 Transport, culture media and storage of bacteria
The specimens for microbiological culture were transported to the laboratory in 0.1
ml isotonic sterile saline and cultured on Campylobacter selective medium
containing 7% horse blood, 10 mg L~1 vancomycin, 5 mg L"* trimethoprim and 5
mg L"1 amphotericin B plus 5 mg L"1 cefsulodin or 2500 IU L~1 polymyxin B or
10,000 IU L~1 colistin. The bacteria were incubated at 37°C in anaerobic jars with a
microaerophillic atmosphere provided by gas generating kit (Campylobacter system
BR60, Oxoid, Unipath Limited, Basingstoke, England) for 3 - 7 days. Bacteria were
stored at -70°C in 25% glycerol and 10% mucin.
2.6.2 Identification ofH. pylori
The bacteria were identified as H. pylori by Gram stain, oxidase and catalase
production and by rapid positive urease test.
2.6.3 Calculation of total bacterial count
A heavy suspension of the bacteria was prepared from growth on plates in PBS and
washed three times by centrifugation at 1000 x g for 20 min. The bacterial pellet
was resuspended in 2 ml of PBS. The optical density (OD) of two fold dilutions of
the washed suspension at 540 nm was determined by a spectrometer (Pye Unicam)
and the total number of bacteria was determined in a counting chamber (Thoma) by
light microscopy. A graph of the OD versus total count was prepared for each strain.
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2.6.4 Standardisation of bacterial concentration for ELISA
The bacteria were harvested from plates with cotton wool swabs, the cell mass was
suspended in PBS and washed three times by centrifugation at 1000 x g for 20 min.
The bacterial concentration was determined from the OD at 540 nm and adjusted
(2.6.3) to 3.2 x 108 bacteria ml""l in coating buffer.
2.7 Buffers used for determination of bacterial binding to BECs
and Kato III cells
2.7.1 Fluorescein isothiocyanate (FITC) buffer
The buffer contained sodium carbonate (0.05 M) and sodium chloride (0.1 M) (pH
9.2). FITC (0.4 mg/ml) (Sigma) was dissolved in the buffer immediately before use.
2.7.2 1% Buffered paraformaldehyde
Buffered paraformaldehyde (1% v/v) was prepared by adding paraformaldehyde
(BDH, 97%) to sodium cacodylate (1% w/v) and sodium chloride (0.75% w/v).
2.8 Bradford reagent for protein estimation
Bradford reagent was prepared from Commasie Blue G250 (0.015 w/v) (Sigma),
ethanol (4.7% w/v) and phosphoric acid (8.5% w/v) in distilled water.
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Chapter 3
Identification of H. pylori in patients with reference to genetic and
environmental risk factors for peptic ulcers
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3.1 Introduction
Several genetic and environmental risk factors for ulcers were identified before the
discovery of the link with H. pylori. The relationships between genetic factors and
ulcer prognosis have been examined since the discovery by Aird and colleagues that
there is an association between blood group O and susceptibility to peptic ulcer.
Non-secretors are over-represented among patients with a variety of bacterial or
fungal infections [Blackwell, 1989] and were reported to be more prone to duodenal
ulcers [Clarke et al., 1956].
The diagnosis of H. pylori infections is dependent on isolating the bacteria from
gastric biopsies obtained at endoscopy or by microscopic identification of the
organism in antral gastric biopsies [Blaser., 1987; Dooley et al., 1989]. Because a
significance proportion of strains of H. pylori were found to be inhibited by some
antibiotics in selective medium [Dent and McNulty, 1988], the sensitivity of local
isolates to these agents needs to be considered in this type of study.
Smoking is a major risk factor for gastric and duodenal ulcers [Friedman et al.,
1974; Kato et al., 1992], a reduction in the healing rate of gastric and duodenal
ulcers [Doll et al., 1958; Korman et al., 1981] and an increase in recurrence of
duodenal ulcers [Sontag et al., 1984; Korman et al., 1983]. Since the use of tobacco
impairs the immune system [Holt, 1987; Cope and Heatley, 1992] and also enhances
colonisation by some bacteria [Fainstein and Musher, 1979], it was considered that
current cigarette smokers might be predisposed to H. pylori infection. The oral
hygiene of smokers is impaired by the residues of tobacco smoke. While it has been
reported that H. pylori was isolated from dental plaque in gingival crevices or
identified by PCR [Krajden et al., 1989; Majmudar et al., 1990; Khandaker et al.,
1991], there has been no systematic examination of these sites in relation to
smoking.
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Patients infected with H. pylori develop a systemic antibody response [Perez-Perez
et al., 1988] and serological assays have been reported to have high sensitivity and
specificity compared with endoscopic culture and biopsy [Perez-Perez et al., 1988;
Talley et al., 1991].
The specific aims of this part of the study were: 1) to compare the sensitivity of local
isolates to the 3 selective antibiotics cefsulodin, polymyxin B or colistin; 2) to study
prospectively the possibility that dental plaque could harbour H. pylori-, 3) to
compare isolation of the bacteria from biopsies with results of a whole cell ELISA
for specific antibodies in serum and saliva; 4) to assess the prevalence of H. pylori
infection in relation to age, ABO blood group, secretor status and cigarette smoking
among patients with dyspeptic symptoms.
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3.2 Patients and methods
3.2.1 Patients
Patients attending outpatient endoscopy clinics at the Western General Hospital,
Edinburgh, Scotland were randomly selected for the study. Informed consent was
obtained and each patient answered a standardised questionnaire to determine age,
history of symptoms of dyspepsia, previous and current medication for symptomatic
control, use of non-steroid anti-inflammatory drugs and antibiotics in the previous 3
months, history of cigarette smoking and dental history (wearing of dentures, oral
hygiene and dental care). The questionnaire (appendix A) was completed by
patients prior to endoscopy.
3.2.2 Collection of blood samples
Blood samples were collected from patients as described (2.3). ABO and Lewis
blood groups for each patient were determined (2.3). The serum was separated and
stored at -20°C for immunoglobulin determination.
3.2.3 Collection of saliva and dental plaque
Saliva (2-5 ml) was collected in sterile universal containers prior to endoscopy and
dental plaque was removed from gingival sides of the canine and molar teeth of each
patient with a sterile dental curette. The specimen was placed in a tube containing
0.1 ml sterile saline solution and plated onto culture medium within 2 h. For patients
with full dentures, dental plaque scrapings were taken from false teeth.
3.2.4 Gastric and duodenal biopsies
Two biopsies were collected from the gastric antrum followed by two further
biopsies from the body of the stomach and one biopsy from the duodenum. One
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biopsy from each site was sent for histology, culture and an additional biopsy was
taken from the antrum for the rapid urease test (CLO test). The antral biopsy was
taken within 2 cm of the pyloric ring. Samples for culture were placed in the neck of
a sterile glass bottle containing 0.1 ml sterile saline to maintain a moist atmosphere
but without destroying the mucus layer within which the H. pylori are to be found
[Dent and McNulty, 1988]. The samples were inoculated onto selective medium
containing 7% horse blood, 10 mg L~* vancomycin, 5 mg L~1 trimethoprim and 5
mg L"1 amphotericin B plus one of the following: 5 mgL'l cefsulodin; 2500 IU L~1
polymyxin B; or 10,000 IU L~1 colistin (2.6.1). The plates were incubated at 37°C
in anaerobic jars with a microaerophilic atmosphere provided by a gas generating kit
0Campylobacter system BR60) for 3 - 7 days (2.6.1) The bacteria were identified as
H. pylori by Gram stain, oxidase and catalase reactions and by the rapid positive
urease test.
3.2.5 Production of rabbit antiserum to H. pylori
A male white New Zealand rabbit was inoculated with a washed suspension of H.
pylori NCTC 11637. Blood (5 ml) was collected before the first inoculation with 1
ml of 2.5 x 10^ bacteria ml~l in PBS mixed with complete Freund's adjuvent. The
immunisation was repeated after one week with the same concentration of the
bacterial suspension in incomplete Freund's adjuvent. After one month, the third
injection of the same concentration of bacteria in PBS was given. A week following
the last immunisation, blood was collected in a sterile container and serum obtained
by centrifugation.
3.2.6 Whole cell ELISA for determination of antibodies to H. pylori in
immune rabbit serum
H. pylori NCTC 11637 grown for 5 days under the conditions described (2.6.1)
were collected and suspended in PBS. The bacteria were heated at 100°C for 60 min
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then centrifuged. The pellet was resuspended in coating buffer (2.1.1) and
standardised by optical density to a total count of 3.2 x 10^ (2.6.3).
Batches of 96 well microtitre plates were coated with 100 pi of H. pylori NCTC
11637 in coating buffer and incubated overnight at 4°C. The plates were washed
with washing buffer (2.1.3) and blocked with blocking buffer (2.1.4) at room
temperature for 20 min. The blocking buffer was removed and the plates washed 6
times with washing buffer.
Non-immune and immune rabbit sera were diluted in blocking buffer and added to
the wells in two different plates, one for determination of IgG and the other for
determination of IgM and incubated at 37°C for 60 min. The plates were then
washed 6 times with washing buffer and goat HRP-anti-rabbit IgG (SAPU) or goat
HRP-anti-rabbit IgM (SAPU) diluted 1/200 in blocking buffer were added to the
plates and incubated for 60 min at room temperature. After washing 6 times in
washing buffer, 100 pi of the substrate (2.1.6) activated immediately before use with
40 ml H2O2 (30% v/v) was added. The colour change was stopped after 10-20 min
by adding 100 pi of H2SO4 (2.1.7). The (OD) at 490 nm was determined by an
ELISA reader (Dynatech) and corrected by subtracting the OD of the corresponding
blank well containing bacteria, HRP-anti-rabbit IgG or HRP-anti-rabbit IgM and
substrate.
3.2.7 Whole cell ELISA for detection of antibodies to H. pylori in serum
and saliva from patients
Batches of 96 well microtitre plates were coated with 100 pi of H. pylori NCTC
11637 and incubated overnight at 4°C as described in 3.2.6. The plates were washed
with washing buffer and blocked with blocking buffer. Serum samples from patients
were diluted 1/100 for IgG, IgM and 1/20 for serum IgA in blocking buffer and
patients saliva diluted 1/5 in blocking buffer. These were added to the wells in
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different plates for detection of IgA, IgM or IgG and incubated at 37°C for 60 min
then washed with washing buffer. Dilutions (1/200) of rabbit HRP-anti-human IgG
(Sigma), rabbit HRP-anti-human IgM (SAPU) or rabbit HRP-anti-human IgA
(Sigma), (100 pi) were added to separate plates and incubated for 60 min at room
temperature. The assay was continued in the same way as the ELISA for
determination of rabbit antibodies to H. pylori. The assays for all patients were
examined at the same time under the same conditions for each of the serum
isotypes. All saliva specimens were examined at the same time under the same
conditions for salivary antibodies.
3.2.8 Statistical methods
The statistical analysis of the data was performed with Statview SE/Macintosh. The
significance levels for differences between two groups were examined with Mann-
Whitney U test and Kruskal-Wallis test for three or more groups. Chi Square test




3.3.1 Correlation between CLO, culture and specific IgG for identification of
H. pylori
From one hundred and twenty patients, 11 patients were withdrawn because
biopsies were not taken so the results could only be analysed in one hundred and
nine patients. Fifty-two patients (47.7%) were found to be H. pylori positive on
culture and/or the Gram stain from the stomach body and antral biopsies; and among
the antral biopsies 48 (92%) were CLO test positive but only 8/52 (15%) duodenal
biopsies were positive on culture.
Table 3.1 shown the clinical characteristics and endoscopic finding in patients who
were H. pylori positive or negative. There were no differences in sex distribution or
dental history between the two groups. There was no peptic ulcer disease in H.
pylori negative patients. Forty patients had peptic ulcer or gastritis; among these
87% were H. pylori-positive by culture from stomach body and antrum biopsies,
77% were H. pylori-positive identified by CLO and 80% H. pylori-positive by
specific IgG. Twenty four patients had oesophageal disease, among these 34% were
H. py/ori'-positive by culture, 29% were H. pylori-positive identified by CLO and
50% H. pylori-positive by specific IgG. Forty-five patients had normal endoscopic
findings, among whom 20% had H. pylori recovered by culture, 17% identified by
CLO and 37% had specific IgG. H. pylori was not isolated from plaque obtained
from the gingival crevices of any of the 109 patients.
3.3.2 Distribution of age among H. pylori-positive patients
Age distribution was assessed among H. pylori-infected patients. H. py/on'-positive
patients had a mean age of 58 years which tended to be older than H. pylori-negative
patients, mean age 46 years, The prevalence of H. pylori infection increased from
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30% in those between the ages of 20 to 30 years to 47% in those between the ages of
40 and 50 years. This increased to 65% at the age of 60 years then decreased to 50%
in those between 70 and 80 years. By the Chi square test, these differences were not
significant (df = 6, X^= =5.42, p = 0.49) (figure 3.1)
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Table 3.1 Detection ofH. pylori among patients referred to gastroscopy clinic
Peptic ulcers Oesophageal disease Normal
n = 40 (%) n = 24 (%) n = 45 (%)
H. pylori +ve +ve +ve
CLO 31 (77) 7 (29) 8 (17)
Culture 35 (87) 8 (34) 9 (20)














Figure 3.1 Age distribution among patients with H. pylori infection
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3.3.3 Distribution of blood group and secretor status in relation to H. pylori
infection
Among 111 patients refered for gastroscopy, 62% were blood group O, 26% were
blood group A, 7% blood group B and 5% were blood group AB. The endoscopic
diagnosis found antral gastritis, duodenitis, gastric ulcer or duodenal ulcer in 40
(41%) patients. These were considered to have significant gastroduodenal disease
but excluded oesophageal disease. Blood group O patients were more likely to have
endoscopically visible gastroduodenal disease 69% compared with 31% of other
blood groups and blood group O patients were more likely to have duodenal ulcer
compared with other disease category, but the differences were not significant (Table
3.2) (df = 2, X2 = 0.84, p = 0.6).
H. pylori was isolated from 33 (49%) of 68 blood group O and 19 (44%) of the 43
patients of other blood groups, but there was no significant prevalence of H. pylori
infection among blood group O patients ( df = 1 , X2 = 2.57, p = 0.1) (Table 3.3).
Non-secretors had more gastroduodenal disease 19/37 (51%) compared with
secretors 20/42 (47%) but this was not significant (df = 1, X2= 0.06, p = 0.8) (Table
3.2). The isolation rate of H. pylori for the two groups was similar, 26/52 (50%)
from secretors and non-secretors.
3.3.4 Distribution ofH. pylori among smoker and non-smoker patients
Among 109 patients there were 40 patients who were smokers, 38 patients who were
non-smokers and 31 patients who were ex-smokers. There were no significant
differences observed in relation to prevalence of gastroduodenal disease among
smokers. Among 52 H. pylori infected patients, there were 18 (34%) patients who
smoked, 20 (38%) non-smokers patients and 14 (26%) ex-smokers, but there was no
significant difference between the 3 groups (Table 3.4).
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A higher prevalence of H. pylori infection was associated with the older age
groups. Among patients referred for gastroscopy, smokers were younger (mean age
= 43 years) compared with non-smokers (mean age = 52 years) and for ex-smokers
(mean age = 58 years). There was a higher prevalence of infection among smokers
compared with non-smokers matched by age but this was not significant (df = 4, X2
= 1.47, p = 0.83) (figure 3.2). There were significant increases in prevalence of H.
pylori infection associated with continuous years of smoking compared with patients
who were H. pylori negative (df = 4, X^ = 14.36, p = 0.006) (figure 3.3). There
were no significant differences in H. pylori infected patients observed for ex-
smokers in relation to age (df = 4, X2 = 3.88, p = 0.42) or years during which they
smoked (df = 2, X^ = 4.1, p = 0.12).
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Table 3.2 Distribution of ABO blood groups and secretor status among patients in
relation to disease category
Group O not- O Secretors non-secretors
n (%) n (%) n (%) n (%)
Duodenal ulcer 14 (77) 4 (22) 8 (44) 10 (55)
n = 18
Pyloric ulcer 6 (50) 6 (50) 6 (50) 6 (50)
n = 12
Gastritis & Duodenitis 7 (70) 3 (30) 7 (70) 3 (30)
n = 10
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Table 3.3 Distribution of ABO blood groups among patients in relation to H. pylori
infection. HP+ = H. pylori present by culture and HP- H. pylori absent.
Blood group
O A B AB
n (%) n (%) n (%) n (%)
* Control (n = 6662) 3323 (50) 2410 (36) 715 (ID 214 (3)
Study group (n = 109) 68 (62) 28 (25) 7 (7) 6 (6)
HP + (n = 52) 33 (63) 13 (25) 3 (6) 3 (6)
HP - (n = 57) 35 (61) 15 (27) 4 (7) 3 (5)
* distribution of ABO in population of Edinburgh [Kinane et al., 1982].
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Table 3.4 Distribution of H. pylori infection among patients with reference to
smoking status and gastroduodenal disease. HP+ = H. pylori present by culture and
HP- H. pylori absent.
HP + HP- disease Normal
n (%) n (%) n (%) n (%)
Number of observations 52 (48) 57 (52) 64 (59) 45 (41)
Current smoker (n = 40) 18 (45) 22 (55) 23 (58) 17 (42)
Ex smoker (n = 31) 14 (45) 17 (55) 20 (65) 11 (35)
Non-smoker (n = 38) 20 (53) 18 (47) 21 (55) 17 (45)
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Figure 3.3 H. pylori infection among smokers with reference to years of smoking.
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3.3.5 Whole cell ELISA for detection of antibodies to H. pylori in rabbit serum
Serial dilutions of rabbit serum before and after immunisation with the whole
bacteria were prepared and assayed for specific IgG with whole cell ELISA. High
absorbency (> 2.050) was observed at dilutions of 1/100, 1/200 and 1/400 of the
immune serum but the absorbence of non-immune serum at the same dilution's were
0.185, 0.072 and 0.022 respectively. A series of dilutions of both immune and non¬
immune serum were used at dilution of 1/800 up to 1/102,400 (figure 3.4).
3.3.6 Determination of serum and salivary antibodies in relation to detection
ofH. pylori
Serial dilutions of serum or saliva were prepared from one patient infected with H.
pylori and another patient who was negative for H. pylori by CLO test, microscopy
and culture to optimise the dilution of serum or saliva to be used to determine the
levels specific serum IgG, IgM and IgA (figure 3.5, 3.6 and 3.7 respectively) and
salivary IgA (Figure 3.8). Dilutions of 1/100 of serum for IgG and IgM or 1/20 for
serum IgA and 1/5 of saliva were found suitable for the assays.
All serum samples were screened for specific IgG, IgM and IgA. There were
significantly higher OD values of serum IgG and serum IgA levels obtained from
patients with H. pylori in the antrum identified by culture, microscopy and/or CLO
(mean IgG OD 1.060 and serum IgA 0.460) compared with H. pylori negative
samples (mean IgG OD 0.200 and serum IgA 0.260) (p < 0.001 for both). There
were no significant differences observed for IgM levels in serum from H. pylori
infected patients compared with non-infected patients (p < 0.4) (figure 3.9).
Saliva specimens were screened at a dilution of 1/5 for specific IgA to H. pylori and
the results showed significant differences with a mean OD of 0.460 for H. pylori
infected patients and 0.370 for non-infected patients (p < 0.01) (Figure 3.9).
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Analysis of the results by the Spearman correlation test found a significant
correlation between the levels of serum IgA and salivary IgA (p < 0.004).
Patients with peptic ulcers had higher levels of serum IgG (mean absorbance of
0.920) compared with gastritis patients (mean absorbance 0.480), oesophageal
diseases (0.450) or no evidence of disease (0.440). By Kruskal-Wallis test, there
were significant differences for specific serum IgG (p<0.001) but not for serum IgM
(p < 0.7), serum IgA (p < 0.3 or salivary IgA (p < 0.2)(figure 3.10)
Serum and salivary antibodies levels against H. pylori was assessed in relation to
blood group and secretor status. Blood group A patients had higher level of serum
IgG and lower level of salivary IgA compared with blood group O, but this was not
significant (by Mann Whitney U test, serum IgG p< 0.2 and salivary IgA p< 0.1).
Patients of group A had significantly higher levels of serum IgA compared with
group O (p < 0.05). Secretors had lower levels of serum IgG, serum IgA and higher
levels of salivary IgA compared with non-secretors, but this was not significant

















800 1600 3200 6400 12800 25600 51200 102400
Dilution
Figure 3.4 Mean of 4 experiments for determination of specific IgG in rabbit serum
before and after immunisation.
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Dilutions
Figure 3.5 Detection of specific IgG to H. pylori by whole cell ELISA. Each point
represents the mean obtained from three replicates of serum from a patient with H.
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Figure 3.6 Detection of specific IgM to H. pylori by whole cell ELISA. Each point
represents the mean obtained from three replicates of serum from a patient with H.
















Figure 3.7 Detection of serum IgA to H.pylori by whole cell ELISA with serum
from a patient with H. pylori isolated from antrum and serum from a patient with no
evidence of infection.
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Saliva of infected patient




Figure 3.8 Detection of IgA specific for H. pylori in saliva by whole cell ELISA.
Each point represents the mean obtained from three replicates of saliva from a
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Figure 3.9 Specific serum IgG, IgM, IgA and salivary IgA to H. pylori of 109
patients, 52 infected with H. pylori (positive) and 57 not infected (negative).
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Serum IgG Serum IgM Serum IgA Salivary IgA
11 Peptic ulcer patients
Ell Gastritis patients
0 Oesophageal disease
0 Normal patients (control)
Figure 3.10 Distribution of specific serum IgG, IgM, IgA and salivary IgA to
pylori among patients with different gastroduodenal diseases.
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Table 3.5 Mean OD of serum IgG, IgA and salivary IgA antibodies against H. pylori















The results of this chapter are assessed in relation to the objectives set in the
introduction.
3.4.1 The effect of antibiotics in selective medium
Among 109 patients referred for gastroscopy, there were 52 patients in whom H.
pylori was identified by CLO test, culture or by stained biopsies. H. pylori was
identified on plates containing polymyxin B, cefsoludin or colistin. Although many
biopsies yield a nearly pure growth of H. pylori, a significant proportion of positives
may be missed when only non-selective media are used [Goodwin et al., 1985].
Skirrow's medium has been used but is not generally recommended because 14% of
the isolates can be inhibited by nalidixic acid, and polymyxin B can inhibit 5% of
isolates [Dent and McNulty, 1988]. In the present study only one isolate was
inhibited by polymyxin B on primary isolation and subculture, and another strain
was inhibited with colistin on primary isolation but it grew on subculture when
tested again with colistin. The best results have been achieved with combinations of
vancomycin, amphotericin, trimethoprim and colistin or cefsulodin in media
supplemented with horse or sheep blood (5% - 10%) or serum with or without
charcoal [Dent and McNulty, 1988; Goodwin et al., 1985]. The results of this
chapter agree that this combination is optimal for primary isolation of H. pylori from
gastric biopsies in the local population.
3.4.2 Assessment of dental plaque for culture of H. pylori
For an infected individual to transmit H. pylori, the organism must leave its
protected environment in the gastric mucus layer and pass into the gastrointestinal
tract. The evidence for isolation of H. pylori from saliva and dental plaque is
contradictory [Krajden et al., 1989 and Bernander et al., 1993]. H. pylori was
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cultured from none of the saliva specimens and from only one dental plaque of 29
patients who yielded positive growth from antral biopsies [Krajden et al., 1989]. In
another study, H. pylori was isolated from dental plaque of asymptomatic volunteers
in India [Majmudar et al., 1990], and Khandaker and colleagues reported the
successful isolation of H. pylori from gingival crevices and dental plaque of patients
with H. pylori associated peptic ulcer disease but the specimens were collected after
gastroscopy [Khandaker et al., 1991]. Although it had been predicted that H. pylori
might be isolated from plaque of smokers, the bacteria were not isolated from dental
plaque of either smokers or non-smokers collected before gastroscopy. This
suggests that the gingival crevices are probably not suitable for growth of these
bacteria.
Polymerase chain reaction (PCR) was used for detection of H. pylori DNA
[Banatvala et al., 1993; Mapstone et al., 1993]. Banatvala and colleagues found//.
pylori DNA in dental plaque by PCR with a primer for the species specific urease
gene. They also detected H. pylori DNA in individuals whose antral biopsies were
H. pylori negative. This could be explained as a false positive result owing to
Helicobacter- like or other urease producing organisms colonising the oral cavity
[Olsson et al., 1993], The organism has been isolated from gastric juice [Andersen
et al., 1988] and a previous study suggested that the oral - oral route of transmission
may be possible from infected individuals who have severe gastro-oesophageal
disease [Khandaker et al., 1991].
3.4.3 Serum and salivary antibodies levels in relation to identification of H.
pylori
Antibodies against H. pylori have been detected in serum by bacterial agglutination,
complement fixation and enzyme-linked immunosorbent assay (ELISA)[Jones et al.,
1986; Goodwin et al., 1987]. Among these methods, the ELISA has proved to be
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the most sensitive and specific test depending on the nature of the antigen [Evans et
al., 1989; Newell., 1987]. Several studies using non-commercial assays have
indicated that serology for H. pylori antibodies is accurate both as a primary
diagnostic procedure and in monitoring the success of treatment of H. pylori
infection [Perez-Perez et al., 1988; Talley et al., 1991]. Studies of H. pylori
associated gastritis in children by an ELISA or indirect immunofluorescence (IIF)
assay found that there were significant decreases in serum IgG and IgA
concentrations within 9-12 months after successful therapy [Oderda et al., 1989;
De Giacomo et al., 1991; Gifone et al., 1993]. The isotypic pattern of H. pylori
specific antibodies appeared to differ in serum, saliva, gastric and rectal mucosa
[Luzza et al., 1995]. H. pylori -specific serum IgG titers were higher than serum
specific IgA; the opposite was observed in the saliva samples as anti-H. pylori IgA
titres were higher than specific IgG titres. In the gastric homogenates, specific IgG
and IgA were similar [Luzza et al., 1995],
In this study, immunisation of a rabbit with whole bacteria induced specific
antibody against H. pylori. Specific rabbit IgG was determined by whole cell
ELISA. The 1/800 dilution distinguished between H. pylori specific IgG and
preimmunization levels, the absorbance was very high at dilutions of less than 1/800,
therefore 1/800 dilutions of rabbit serum was used in the ELISA assays as positive
and negative controls.
H. pylori specific serum IgG, IgM, IgA and salivary IgA in patients were determined
by whole cell ELISA. The results confirmed the diagnostic value of ELISA for
determination of serum IgG antibodies against H. pylori and showed that 1/100
dilutions of serum and 1/5 dilutions of saliva distinguished between H. pylori
infected and non-infected patients. These findings are in agreement with previous
reports [Vaira and Holton., 1989, Kosunen et al., 1992 and Gifone et al., 1993], but
different from those reported for adults by using IIF test for specific IgG which
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showed overlapping between the H. pylori positive and negative groups of patients
[Faulde et al., 1991].
A number of ELISA tests using whole bacteria as antigen have been developed for
epidemiological and diagnostic purposes [Floegtad et al., 1990]. The assay has
proved sensitive and reproducible and has been satisfactory for all bacteria
examined. The technique for coating the bacteria is easy to perform and the method
can be applied to a wide range of patients for primary diagnostic and
epidemiological studies. The results of the ELISA assay correlated well with the
presence of H. pylori in gastric biopsies and the assay differentiated between patients
with and without peptic ulcers. These results suggest that ELISA might be useful
for screening patients refered for endoscopy thereby reducing the endoscopy list in
the clinic; however, sera samples could also test negative for H. pylori antibodies
despite a prior infection. It has also been reported that a quarter of gastric cancer
patients who tested seronegative in an ELISA, tested positive using Western blotting
[Crabtree et al., 1993],
3.4.4 Assessment of risk factors for peptic ulcer disease in relation to clinical
and laboratory finding
Prevalence of H. pylori infection is associated with increasing age, lower socio¬
economic status and certain racial groups [Graham et al., 1991]. H. pylori infection
is more prevalent in the developing world where infection occurs early in childhood
and may rise to over 80% in young adults [Sullivan et al., 1990]. In developed
countries the prevalence of infection increases with age at the rate of 15% per annum
and reaches 60 - 70% by the age of 70 years [Graham et al., 1991]. There are two
possible explanations for the correlation between increasing age and infection. First
infection may be acquired gradually throughout life; second this could be a cohort
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effect reflecting lower socio-economic standards during the childhood period of the
elderly population.
This study found that H. pylori positive patients tend to be older than non-infected
patients and prevalence of the infection increased with increasing age. This is in
agreement with data obtained from other epidemiological studies of seroprevalence
rates in different age groups in developed countries [Graham et al., 1991; Sitas et al.,
1991; The Eurogast study group, 1993]. In this study the peak of H. pylori positive
patients was found in the group aged between 50 - 60 years old, whereas the rate
tended to be lower in older patients. This has been noted previously by other groups
[Dwyer et al., 1990; Sandro et al., 1993] and this has been associated with
progression of chronic H. pylori gastritis to atrophic gastritis in elderly people,
because severe gastric atrophy seems to make the stomach inhospitable to H. pylori
[Goldschmiedt et al., 1991, Kaneko et al., 1992], There were no significant
differences in rate of infection in the older age group among patients with
gastroduodenal disease compared with normal histology.
Individuals of blood group O are significantly over represented among patients with
gastric or duodenal ulcers compared with patients of the other blood groups for both
British and Greek patients with ulcers [Langman and Doll, 1965; Merikas et al.,
1986; Mentis et al., 1991]. Mentis and colleagues found no association between
presence of H. pylori and blood group O [Mentis et al., 1991]. Another study found
a correlation between ABO blood group and H. pylori infection in 42 patients with
rheumatoid arthritis aged 50 - 66 years. Blood group O patients had H. pylori in the
antral mucosa more frequently than patients of other blood groups [Henriksson et al.,
1993]. It is known that most patients with duodenal ulcers are colonised with H.
pylori [Tytgat and Rauws, 1990] and the association of duodenal ulcers with blood
group O is well established [Semble et al., 1987 and Mentis et al., 1991]. Others
have claimed that H. pylori infection is not associated with the ABO blood group,
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but in that study only a serological evaluation of H. pylori infection was made
[Hook-Nikanne et al., 1990]. In the present study, blood group O was over
represented among patients with gastroduodenal disease and among patients with H.
pylori infection in antral biopsies, but this was not significant. This observation
might be due to the small number of patients involved in the study and differences in
patient's ages which is a risk factor for H. pylori infection.
Non-secretors of blood group antigens was reported to be over-represented among
patients with several bacterial or fungal infections or symptomatic carriers (Table
1.6). The increased prevalence of gastroduodenal disease in non-secretors might be
associated with an increased susceptibility to H. pylori infection. Non-secretion of
blood group antigens was a significant risk factor for gastroduodenal disease without
ulcers in 101 patients with dyspeptic symptoms studied endoscopically, but was not
associated with the presence of H. pylori in antral biopsy specimens [Dickey et al.,
1993]. Another study in 185 patients with dyspepsia but not peptic ulcer showed no
significant association between H. pylori infection and secretor status [Chesner et
al., 1992], Similar results were observed among 271 blood donors which found no
association between H. pylori antibodies and secretor status but endoscopy was not
performed [Hook-Nikanne et al., 1990] Mentis and colleagues showed no
association between secretor status and H. pylori infection or secretor status with
duodenal or gastric ulcers among 454 patients assessed by endoscopy [Mentis et al.,
1991]. The results of this chapter agree with previous studies; there was not an
increase in prevalence of H. pylori infection or salivary IgA levels among non-
secretors patients compared with secretors. There was a higher level of serum IgG
among non-secretors compared with secretors but this was not significant.
Epidemiological studies found that cigarette smoking is associated with an increased
risk for developing duodenal ulcer as well as with a greater incidence of ulcer-related
complications including death [Trowell., 1934; Doll and Hill., 1964]. Smoking
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delays ulcer healing and increases the risk of recurrence [Korman et al., 1981;
Ostensen et al., 1985]. The risk of gastric ulcer is increased among current smokers
when compared with those who have never smoked, and higher gastric ulcer rates
are found among heavy smokers than light smokers [Stemmermann et al., 1989].
Clinical evidence showed that smoking increased the risk of H. pylori infection and
current cigarette smokers had a higher rate of H. pylori infection than non-smokers
and ex-smokers [Bateson, 1993], There was also a strong correlation between active
H. pylori infection itself and cigarette smoking in the group with normal endoscopy.
This has been controversial [Graham et al., 1991; Braverman et al., 1990]. The
present study is in agreement with previous findings that smokers are more at risk
for gastroduodenal disease, but there was no correlation between H. pylori infection
isolated from antral biopsies or serum and salivary antibody levels and smoking.
Age was found to be an important factor for H. pylori infection. The results showed
a significant increase of H. pylori infected patients among smokers compared by
years of smoking, which indicates that smoking and age are a risk factors for H.
pylori infection.
3.4.5 Conclusion
Most serological studies on H. pylori infection have been qualitative rather than
quantitative. The present study differed in that a semiquantitative method was used
to assess antibody levels. The results reported by Kreuning et al., [1994], that IgG
level correlated with density of colonisation indicate that this work needs to be
expanded with larger numbers of patients with different diseases related to H. pylori
infection.
The risk factors reported for peptic ulceration examined in this study (blood group,
secretor status and smoking) did not appear to influence frequency of colonisation by
H. pylori. The observations by Mentis et al., [1991] and more recently by Atherton
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et al., [1996] suggest that density of colonisation is related to development of
disease. In the next chapter, flow cytometry was used to address the effects of these
risk factors on bacterial binding and density of colonisation of epithelial cells.
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Chapter 4
Risk factors for peptic ulcers and binding of Helicobacter pylori to
human BECs and gastric adenocarcinoma cells (Kato III)
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4.1 Introduction
A number of years before the association between H. pylori and peptic ulcers was
demonstrated, non-secretors and individuals of blood group O were found to be
over-represented amongst patients with peptic ulcer [ summarised by Mourant et al.,
1978 ]. Studies in this and other laboratories have found that the epithelial cells of
non-secretors bind larger numbers of a variety of micro-organisms than cells of
secretors : uropathogenic strains of E. coli [Lomberg et al., 1986 ]; C. albicans
[May et al., 1989]; S. aureus [Saadi et al., 1993 ].
Two blood group antigens common to most individuals have been proposed to act as
receptors for micro-organisms, H type 2 and Lewisa [Blackwell, 1989 ]. H type 2,
the antigen of blood group O, is found on the cells of all individuals except the very
rare Bombay phenotype [Race and Sanger, 1975 ]. The Lewis antigens on epithelial
cells are adsorbed from secretions and reflect those present in the body fluids.
Individuals who are non-secretors can only express the Lea antigen whereas
U n
secretors predominantly express the Le antigen and highly variable amounts of Le
[Saadi et al., 1993]. Boren and colleagues suggested that Lewis'5 is the receptor for
H. pylori in their experimental system. As the Lewis'5 antigen is absent from cells
or body fluids of non-secretors, this cannot explain the apparent increased
susceptibility of non-secretors to peptic ulcers [ Boren et al., 1993]
Since the turn of the century, evidence has been accumulating that peptic ulcers and
smoking are strongly associated. There is a significantly increased (about two fold )
prevalence of both duodenal and gastric ulcers in smokers compared with non-
smokers [Harrison et al., 1979].
The objectives of this part of the study were : 1) to determine if H type 2 and the
Lewis blood group antigens were expressed on the Kato III (gastric adenocarcinoma
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cell line) and gastric mucosa cells; 2) to test the hypotheses that in addition to Le*\
H type 2 or Lea were receptors for these bacteria; 3) to determine if secretor status,
ABO blood group, smoking or fasting affect the bacterial binding or the expression
of blood group antigens.
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4.2 Materials and methods
4.2.1 Bacterial strains and culture
H. pylori, strains NCTC 11637 and NCTC 11916 were obtained from the Central
Public Health Laboratory (Colindale) and cultured as described in chapter 2 (2.8.1
and 2.9.2).
4.2.2 Labelling of H. pylori with FITC
Bacteria were labelled with FITC by a modification of the method of Wright and
Jong [1986]. A heavy suspension of bacteria was prepared and washed twice by
centrifugation at 1000 x g for 20 min. The bacterial pellet was resuspended in 4 ml
of freshly prepared FITC (2.6.1). The mixture was incubated at 37°C for 30 min and
washed three times with PBS. The pellet was resuspended in PBS and the
concentration determined by OD at 540 nm (2.6.3)
4.2.3 Gastric adenocarcinoma cells (Kato III)
Kato III cells were prepared as described in (2.2), washed twice with PBS and the
concentration adjusted to 2.5 x 10^ cells ml"1 following determination of the total
number of cells microscopically with a Neubauer haemocytometer counting chamber
4.2.4 Buccal epithelial cells (BEC)
Buccal epithelial cells (BEC) were obtained from healthy members of the Medical
Microbiology Department or patients from the endoscopy clinic whose ABO blood
group and secretor status had been determined. To test the effect of fasting, BEC
from healthy male volunteers were collected during Ramadan when they were
fasting 12 - 18 h/day and tested in parallel with cells collected from the same
individuals when they were not fasting.
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The cells were collected by rubbing the inside of the cheeks with cotton swabs. To
remove the cells, the swabs were agitated in 10 ml of PBS. The cells were then
washed twice in PBS by centrifugation at 300 x g for 10 min. The cells were
counted in a haemocytometer then adjusted to 2.5 x 105 cells ml"1 .
4.2.5 Gastric mucosa cells
Gastric mucosa cells were obtained from patients by means of a cytology brush. The
gastric cells were washed twice by centrifugation in PBS at 300 x g for 10 min and
adjusted with a Neubauer haemocytometer to 2.5 x 10^ cells ml"1.
4.2.6 Binding assay
4.2.6.1 Binding assay by light microscopy
Binding of H. pylori NCTC 11637 to BEC was assessed as described by [Mahajan
and Panhotra, 1989]. Equal volumes of a BEC (500 jxl) and bacterial suspension
were mixed together in a plastic tube and the mixture was incubated at 37°C in an
orbital incubator for 60 min. The cells were washed three times with PBS by
centrifugation at 300 x g for 10 min to remove unattached bacteria. Smears were
prepared from the centrifuged deposit, air dried, fixed with methanol for 5 min,
stained with Gram's stain and examined by light microscopy with an oil immersion
lens.
4.2.6.2 Binding assay by flow cytometry
Buccal cells or Kato III cells (200 pi, 2.5 x 10^) were mixed with 200 pi of dilutions
of the FITC-labelled bacteria to produce different ratios of bacteria per cell. To
determine the optimal incubation period, the samples were incubated at 37°C for 0,
30 and 60 min with gentle shaking (100 rpm) in an orbital incubator (Gallenkamp).
The cells were washed twice with PBS by centrifugation at 300 x g for 10 min to
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remove unattached bacteria, resuspended in 150 |il of PBS and fixed with 100 jil of
1% buffered paraformaldehyde. They were stored in the dark at 4°C until analysed.
4.2.7 Analysis of cells by flow cytometery
Analysis was done on an EPICS "XL" flow cytometer (Coulter Electronics, Luton,
UK) equipped with a 55 W laser using a power output of 200 Mw at 488 nm. The
cells were selected from a display of forward angle light scatter versus 90° light
scatter by means of a bit map. A minimum of 1000 cells were analysed from each
sample. The percentage of cells showing fluorescence greater than the background
(cells without bacteria) level was recorded on a one parameter histogram measuring
fluorescence on a logarithmic scale. The mean fluorescence channel values for the
positive cells were obtained from a conversion table of log fluorescence supplied by
the manufacturer (Coulter). The results were analysed by the immunoanalysis
program (Coulter), a computer programme that subtracts the values of the control
population from the test population at each channel of the two histograms (fig 4.1).
The binding index of each sample was calculated by multiplying the percentage of




Figure 4.1 Flow cytometric analysis with FITC-conjugated bacteria attached (B)
compared to control cells with no bacteria (A)
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4.2.8 Detection of Lea, Le'} and H type 2 on BECs and Kato III cells
Cells were washed and the concentration adjusted to 2.5 x 10^ ml"1. Cells (200pl)
were added to Falcon tubes containing either 200 pi of PBS as control or 200 pi or
monoclonal antibodies diluted in PBS: anti-Lea (1 in 5); anti-Le^ (1 in 5); or anti-H
type 2(1 in 5) (see table 2.1). The tubes were incubated at room temperature for 60
min, the cells were washed twice in PBS at 300 x g for 10 min. FITC-conjugated
anti-mouse IgM (200pl, 1:200 in PBS) was added to each sample and incubated at
37°C for 30 min with gentle shaking. After washing twice in PBS at 300 x g for 10
min, the samples were fixed with 200 pi of 1% buffered paraformaldehyde and
stored in the dark at 4°C until analysed with the EPICS-XL flow cytometer.
4.2.9 Inhibition of binding by pretreatment of BEC or Kato III cells with
antibodies to cell surface antigens
BEC or Kato III cells were washed and the concentration adjusted as before. The
cells (200 pi) were incubated with 200 pi of PBS or dilutions of the monoclonal
antibodies against H type 2, Lea or Le^ in 4.2.8 for 30 min at 37°C with gentle
shaking (100 rpm) in an orbital incubator (Gallenkamp) and washed twice to remove
unbound antibodies. FITC-labelled bacteria at a concentration of 300 bacteria per
cell were added to Kato III cells or BEC pre-treated with PBS or monoclonal
antibodies. The cells were washed twice with PBS by centrifugation at 300 x g for
10 min to remove unattached bacteria. The samples were resuspended, fixed and
stored as before until analysed. Calculation of inhibition of bacterial binding was
calculated from the binding indices of test and control sample with the following
formula: % of inhibition = 100 - [(test / control) x lOO].
4.2.10 Statistical methods
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The statistical analysis of the data was performed with Statview SE/Macintosh. The
significance levels for differences between two groups were examined with Mann-
Whitney U test or by the Rank Sum test.
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4.3 Results
4.3.1 Correlation of total bacterial count with optical density
The correlation between the readings of optical density (OD) at 540 nm with total
bacteria count for each strain of H. pylori tested is shown in figure 4.2
4.3.2 The effect of FITC on bacterial binding
To examine the effect of FITC on binding of the bacteria to BEC, binding of FITC-
labelled and unlabelled H. pylori NCTC 11637 were examined on 5 different slides
by light microscopy; 20 cells were counted for each slide. There were no significant
differences in binding of FITC-labelled bacteria (mean 58) compared with
unlabelled bacteria (mean 52) at concentration of 100 bacteria per cell.
4.3.3 Optimal conditions for binding and inhibition studies.
Different concentrations of FITC-labelled bacteria were incubated with BEC to
determine optimal incubation time, pH and ratios of bacteria per cell. No
fluorescence above background levels was observed when bacteria were added to
BEC immediately prior to analysis. Attachment increased for the first 30 min then
the increase was less rapid as shown in figure 4.3 (mean of 2 experiments); 60 min
was used as the standard incubation time for the binding assays.
Attachment of H. pylori to BECs was examined with five different concentrations of
bacteria / cell (1200, 600, 300, 150 and 75). Figure 4.4 represents the mean of 4
experiments. For further experiments, ratios between 150 - 600 bacteria / cell were
used.
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Figure 4.5 illustrates the mean of 2 experiments to assess the effect of pH on binding
of H. pylori to BECs. There were no significant differences between pH 3.9, 6.0 or
7.3; therefore pH 7.3 was used for further attachment assays.
4.3.3 Expression ofH type 2 and Lewis blood group antigens on epithelial
cells
Binding of monoclonal antibodies to H type 2, Lewisa and Lewis^ antigens was
demonstrated for the Kato III cells, BEC and gastric mucosa cells. Figure 4.6
represents the mean of four experiments to assess binding of monoclonal antibodies
against H type 2 and the Lewis antigens to Kato III cells.
Table 4.1 illustrates binding of these antibodies to gastric mucosal cells obtained
from four patients. The small number of cells available did not allow repeat studies
from the same patient.
Buccal epithelial cells from healthy individuals bound all three monoclonal
antibodies and those from individuals of group O (n = 7) had significantly higher
binding indices for anti-H type 2 (mean = 1536) when compared by the Rank Sum
test with binding indices for non-0 donors (n = 7) (mean = 347) (p< 0.05) (Figure
4.7). There were no significant differences in binding indices for anti-Lewis
antibodies for secretors compared with non-secretors. There were no differences in
binding indices for males compared with females.
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1.0-1
Figure 4.2 Total bacterial count (x 10^) determined by microscopy versus optical
density of H. pylori strains NCTC 11637, NCTC 11619, isolates from duodenal







Figure 4.3 Time response of binding of H. pylori NCTC 11637 to BEC at the
following ratios of 1200, 600, 300, 150, 75 bacteria : cell.
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Figure 4.6 Mean binding indices of four experiments to assess the attachment of
monoclonal antibodies against Lea, Le^ and H type 2 to Kato III cells.
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Table 4.1. Binding ofmonoclonal antibodies against Lea, Leb or h type 2 to gastric




























ED Not group 0
Figure 4.7 Binding of monoclonal antibody against H type 2 to BEC obtained from
blood group O (n = 7) and non-O individuals (n = 7)
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4.3.4 Binding of H. pylori to BEC with reference to ABO blood group
and secretor status
Binding experiments with H. pylori NCTC 11916 and BEC from 8 secretor and 8
non-secretor donors with no history of gastrointestinal disease found that the mean
binding index for secretors was 8669 and for non-secretors was 7118; the mean
binding index of H. pylori NCTC 11637 to cells of secretors (7925) was also
greater than to the cells of non-secretors (5640). By the Rank Sum test, there was
no significant different in binding of H. pylori to cells from secretors compared with
cells from non-secretors. There was no significant difference in detection of the
Lewis antigens on BEC of secretors and non-secretors assessed by binding of
monoclonal antibodies to the antigens in the flow cytometry assays (Table 4.2).
There was a significant difference in detection of H type 2. As the donors had not
been matched for ABO groups, the experiment were repeated to assess the effect of
ABO blood group.
The experiments were repeated with cells from gastroscopy patients who were non-
smokers. The binding indices of H. pylori NCTC 11637 with buccal cells from 7
group O secretor patients was significantly greater than with BEC from 7 patients
who were non-O secretors (p<0.05) (figure 4.8). Binding of H. pylori NCTC 11637
to BEC assessed by secretor status found that the mean value for binding indices
with cells from 7 group O secretors was significantly greater then the cells from 7
group O non-secretors p < 0.01 (figure 4.9).
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Table 4.2. Mean binding index of H. pylori NCTC 11916 and NCTC 11637 to
BECs of healthy donors and expression of blood group antigens (n = number of
donors, NS = not significant).
H. pylori NCTC 11916
H. pylori NCTC 11637
Expression Lea
Expression Le^
Expression H type 2
Secretors Non-secretors
















Group O Not group O
Figure 4.8 Binding of H. pylori NCTC 11637 to BEC from patients of blood group
O (n = 7) and not group O (n = 7) (P<0.05).





















Figure 4.9 Binding of H. pylori NCTC 11637 to BEC from patients of blood group
O secretors (n = 7) and group O non-secretors (n = 7) (P<0.01).
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4.3.5 The effect of exposure to cigarette smoke on adherence of H. pylori
to epithelial cells
Binding of 2 strains of H. pylori NCTC 11637 and NCTC 11916 was examined with
BEC from students and staff in the Department of Medical Microbiology, 8 were
smokers and 8 were non-smokers. The mean binding index of NCTC 11637 for
smokers (2392) was higher than that for non-smokers (1510). A similar pattern was
found for NCTC 11916; the binding index for smokers (7021) was higher than for
non-smokers (5899). By the Rank Sum test, there was no significant difference in
binding of H. pylori to cells from smokers compared with cells from non-smokers
(Fig 4.10)
In another set of experiments with BEC from patients, binding of H. pylori NCTC
11637 to cells from 6 smokers and 6 non-smokers was examined. The results
showed that the mean binding index for smokers was 68 744 and mean binding
index for non-smokers was 58 949; by the Rank Sum test, there was a significant
difference in binding of H. pylori to BEC cells from smokers compared with cells
from non-smokers (p<0.05) (Fig 4.11). In another set of experiments, the mean
binding index of H. pylori to BEC from 7 patients who were smokers (40 301) was
significantly higher than to cells of 7 non-smokers (28758) (p< 0.001). The smokers
had a significantly higher binding indices for anti-H type 2 than non-smokers (p<
0.02) but with anti-Lewisa and Lewis'5 the differences were not significant (Table
4.3). There was no significant differences in medication for the patient groups;
however, the patients had fasted overnight before the cells were collected; therefore,
a larger group of healthy individuals were tested for the effect of smoking and
fasting (4.3.6).
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4.3.6 The effect of fasting on the binding ofH. pylori to BECs
As the gastroscopy patients had fasted for approximately 12 hours before collection
of cells, the binding studies were repeated with BEC from 30 Muslim males during
Ramadan when they were fasting approximately 12 - 16 hr per day. The same
donors were examined after the fast when they were eating and drinking normally.
Figure 4.12 illustrates the results of 15 smokers and 15 non-smokers for bacterial
binding and expression of blood group antigens. By the Rank Sum test there was
significantly higher binding of H. pylori to cells from non-smokers compared with
cells from smokers (p<0.001), and there were significantly higher binding indices for
monoclonal antibodies to Lea (p<0.002), Le^ (p<0.005) and H type 2 (p<0.001) on
the cell surfaces of non-smokers. For the 30 healthy donors, binding indices for H.
pylori were significantly correlated with binding indices for anti-H type 2 (P< 0.005)
and anti-Le^ (P < 0.001) but not with anti-Lea.
Bacterial binding to cells from 7 fasting non-smokers was significantly higher than
for cells from 7 fasting smokers (P< 0.002) and there were significantly higher
binding indices for monoclonal antibodies to Lea (p<0.002), Le^ (p<0.005) and H
type 2 antigens (p<0.001) on the cell surface of fasting non-smokers compared with
cells of fasting smokers. There was significantly higher bacterial binding to cells
from 8 non-smokers who were not fasting compared with 8 smokers who were not
fasting (P< 0.002), and there were significant differences in binding of monoclonal
antibodies to H type 2 to cells of non-fasting non-smokers compared with cells of
non-fasting smokers (P< 0.005). There was no significant difference in binding of
the monoclonal antibodies to the Lewis antigens. There was no significant
difference in bacterial binding to cells from not-fasting donors compared with cells
from fasting donors, binding of anti-H type 2 to cells of non-fasting donors was
higher (p< 0.001), but there was no significant difference in binding of antibodies to
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NCTC 11637 NCTC 11916
Figure 4.10. Binding of H. pylori NCTC 11637 and NCTC 11916 to BEC from















Figure 4.11. Binding of H. pylori NCTC 11637 to BEC of 6 smokers and 6 non-
smokers referred to the gastroscopy clinic (P<0.05).
119
Table 4.3 Comparison of mean binding indices for H. pylori NCTC 11637 and
monoclonal antibodies to Lea, Leb and H type 2 for BECs obtained from smokers (n
= 7) and non-smokers (n = 7) attending gastroscopy clinics.
Smokers Non-smokers
n = 7 n = 7 P
Bacterial binding 40 301 28 758 0.001
Anti-Lea 64 721 57 488 NS
Anti-Leb 23 692 16 811 NS


















Figure 4.12. Comparison of mean binding indices for H. pylori NCTC 11637 and
monoclonal antibodies to Lea, Le^ and H type 2 for smokers (n = 15) and non-
smokers (n = 15) of healthy donors.
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Table 4.4. Comparison of binding indices for H. pylori and monoclonal antibodies
specific for H type 2, Lea and Le^ to buccal epithelial cells from smokers (n = 15)
and non-smokers (n = 15) with reference to fasting
Fasting Non-fasting
Smokers Non-smokers Smokers Non-smokers
n = 7 n = 7 p* n = 8 n = 8 P*
H type 2 650 2688 <0.001 2102 4852 <0.005
Lewis3 47229 58102 <0.002 45359 51031 NS
Lewis'3 7067 17907 <0.005 7902 11869 NS
H. pylori 28815 37299 <0.002 25802 37819 <0.002
* assessed by Rank Sum test
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4.3.7 Inhibition of bacterial binding with monoclonal antibodies to H type
2 and Lewis antigens.
In assays with BEC from 12 patients referred for gastroscopy, binding of H. pylori
strain NCTC 11637 was inhibited with anti-Lea (28 %), anti-Le^ (25 %) or anti-H
type 2 (Serotec) (12 %). The results were analysed by the Wilcoxon Matched-pairs
test and there was significant inhibition with monoclonal anti-Lea (p<0.02) and anti-
Leb (p<0.05) but not with anti-H type 2 (figure 4.13). Treatment of Kato III cells
with different concentrations of monoclonal antibodies against Lea, Le^ and H type
2 inhibited binding of H. pylori NCTC 11637. By the paired t-test, there was no
significant difference (figure 4.14).
Assays for inhibition of bacterial binding were also carried out with additional
bacterial isolates; two of the isolates were from patients with duodenal ulcers, two
isolates were from patients with no histological evidence of disease. Binding of the
local isolates and H. pylori NCTC 11637 was inhibited by pretreatment of Kato III
cells with monoclonal antibodies to H type 2 and Lewis antigens, the mean
percentage inhibition was 36 % with anti-Lea, 35 % with anti-Le^ and 38% with
anti-H2 (figure 4.15). Additive effects on inhibition were observed with











HI Anti-H type 2
Figure 4.13. Inhibition of bacterial binding of H. pylori NCTC 11637 by










Figure 4.14. Titration of monoclonal antibodies against Lea, Le^ or H type 2 to









^ Anti-H type 2
DU 1 DU 2 N 1 N 2 NCTC 11637
Figure 4.15 Inhibition of bacterial binding of five isolates to Kato III cells
preincubated with concentrated monoclonal antibodies against H type 2 and Lewis
antigens (DU = isolates from duodenal ulcer patients , N = isolates from patients




01 Anti H type 2
B Anti-Lea + Le^
H Anti-Lea + H type 2
H Anti-Le^ + H type 2
H Anti-Lea +Le^ + H type 2
Kato III cells
Figure 4.16. Mean of four experiments to assess the inhibition of binding of NCTC
11637 to Kato III cells by pre-treatment of cells with monoclonal antibodies against
Lea, Leb, H type 2 or combinations of these antibodies
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4.4 Discussion
The results of this chapter are assessed in relation to the methodology employed and
the objectives set out in the introduction
4.4.1 Methods for assessment of bacterial binding
A number of different techniques have been used to measure the attachment of
bacteria to cells. There were several problems associated with the light microscopy
method for assessment of bacterial binding, e.g, bacteria were not distributed over
BEC, it is time consuming to count reasonable numbers of cells and the number of
bacteria varied greatly. Comparison between FITC labelled and unlabelled bacteria
for binding of H. pylori NCTC 11637 to BEC assessed with the light microscopy
found no effect of FITC labelling on bacterial binding. The numbers of cells that
can be assessed, the accuracy of count and possible bias by the person counting the
cells are all factors that limit the use of this method.
Flow cytometry provided a powerful tool for analysing bacterial binding. It was
possible to approximate differences in the numbers of bacteria per cell by the
changes in the fluorescence intensity of the cells and it was also possible to detect a
positive signal from cells even when cells were incubated with smaller numbers of
bacteria. It is a reliable and practical method and large numbers of cells can be
analysed in a short period of time. Dyes such as fluorescein isothiocynate (FITC)
that bind covalently to protein amino groups are preferable to other acid dyes
because the washing procedures lower background fluorescence [Shapiro, 1990],
Direct labelling of bacteria with FITC has been used for adhesion assays by other
workers [Svenson and Kallenius, 1983; Saadi et al., 1993; Raza et al., 1993], and
direct labelling of Helicobacter pylori with FITC was used for binding and
inhibition studies with human and rat gastric epithelium cells [Falk et al., 1993],
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Helicobacter pylori has been shown to bind to a large range of cell types in vitro.
These cells include human buccal epithelial cells, mouse Y-l adrenal cells, HEp-2
cells, Int-407 cells, HeLa cells, Kato III cells and primary epithelial cells isolated
from gastric, duodenal and colonic biopsy specimens [ summarised by Clyne and
Drumm, 1993]. BEC were chosen for the binding assays because of their ready
availability and the expression of blood group antigens under investigation on their
cell surfaces. Although many cells are dead and there are variations in size of the
cells, they have been used for binding assays with many bacterial species: type II
Group-B Streptococcus pyogenes [Bagg, 1982], Neisseria meningitides [Craven and
Frasch, 1978], Streptococcus pneumonia [Mahajan and Panhotra, 1989] and
Staphylococcus aureus [Beck, 1989; Saadi et al, 1993].
4.4.2 Expression of proposed receptors on BEC, gastric cells and Kato III
cells
The first objective of the study was to determine if the blood group antigens
proposed to act as receptors for H. pylori were present on gastric mucosa, BEC and
Kato III cells to be used in binding and inhibition studies. The small numbers of
mucosal cells obtained from gastroscopies precluded their use in the bacterial
binding assays. Monoclonal antibodies against H type 2, Lea or Leb bound to each
of the cell types tested. The binding of anti-Leb to cells from non-secretors
observed in this study (Table 4.2) was probably due to the cross reactivity of anti-
Leb with both Lea and with H related structures [Good et al., 1992], Previous
studies of human gastric carcinoma and normal gastric tissue has demonstrated
blood group antigens by immunohistochemical methods [Sakamoto et al., 1989], and
the present study confirmed the expression of these blood group antigens on the cell
surface of normal gastric tissue and gastric adenocarcinoma cell line by the flow
cytometry technique.
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There was no difference in expression of these antigens between males and females;
therefore, BEC from 30 healthy male donors were used to assess the effects of
smoking and fasting on expression of these antigens. Fasting significantly reduced
binding of the monoclonal antibody to H type 2 but not binding of monoclonal
antibodies against Lewis antigens. Binding indices for all three monoclonal
antibodies were significantly lower for cells from smokers compared with non-
smokers. This might be due to components of the cigarette smoke covering the
antigen on epithelial cell surfaces.
4.4.3 Role of blood group antigens as receptors for H. pylori
The second objective was to determine if in addition to Le^ previously identified as
a receptor for H. pylori [ Boren et al., 1993], Lea or H type 2 could also act as
receptors for the bacteria. Boren et al [1993] found no strong evidence for the
involvement of fucose-containing blood group antigens other than Lewis** in binding
of H. pylori in their model system [Boren et al., 1993]. In contrast, the results of this
chapter indicate that antibodies to H type 2, Lea or Le*> were capable of inhibiting H.
pylori binding to Kato III and BEC. This might be due to different methods as
Boren et al used tissue sections and assessed binding microscopically. This study
examined cells in suspension and detected binding by flow cytometry. Different
monoclonal antibodies were used in the two studies, and one of the monoclonal
antibodies to H type 2 (SAPU) did not inhibit binding in these studies.
The results of the bacterial binding studies with BECs from 30 individuals indicated
that the binding indices for H. pylori were significantly associated with binding
indices for monoclonal antibodies to H type 2 (P< 0.005) and Le*> (P< 0.001) but not
with Lea. Pretreatment of Kato III or BECs with the monoclonal antibodies to each
of the three blood group antigens reduced the binding of H. pylori. For the Kato III
cells, the binding indices for anti-Lea were higher than for the other two antibodies
130
but inhibition of bacterial binding was greatest with anti-H type 2 followed by anti-
Leb with the lowest inhibitory effect noted for anti-Lea. For BECs from patients
referred for gastroscopy, the inhibition of bacterial binding was greatest with Lea
followed by Le^ then H type 2. These different inhibition results might be due to the
amount of blood group antigens expressed on the cell surface of different cells.
These results suggested that blood group antigens (H type 2, Lea and Le^) might
play an important role in attachment of H. pylori to the gastric mucosa. In each set
of experiments with BEC, binding indices of H. pylori was correlated with binding
indices for H type 2, indicating that H type 2 found on almost all individuals is a key
receptor for H. pylori. The increased susceptibility of group O individuals to peptic
ulcer disease might be due partly to higher density of colonisation by these bacteria
compared with other blood groups.
While both secretors and non-secretors express H type 2, these results indicate the
higher levels of Le^ in mucus of secretors might compete more effectively for the
adhesin than Lea, thereby reducing density of colonisation among secretors. The
terminal fucose structure present on blood group antigens found in body fluid of
secretors as in the H type 1 structure found in Lewis'3, A-Lewis^ or B-Lewis'3 might
bind to the adhesin and reduce colonisation.
4.4.4 The effects of smoking and fasting on bacterial binding and
expression of blood group antigens
Smokers have been shown to have enhanced adherence of Strept. pneumonia to BEC
[Mahajan and Panhotra, 1989; Raman et al., 1983; El-Ahmer et al., 1996], and
smokers with chronic bronchitis appear to have increased binding of H. influenzae to
their pharyngeal cells [Fainstein and Musher, 1979]. While smoking has been
identified as a risk factor for ulcers, the present study with BEC suggest that in
healthy individuals smoking does not result in increased expression of H type 2 or
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Lewis blood group antigens. If there are similar effects on epithelial cells lining the
gastric mucosa, smoking would not be expected to enhance bacterial binding. Both
sets of experiments with cells from patients found higher bacterial binding to cells of
smokers. There were also increased levels of binding of anti-H type 2 to the cells of
smokers in the second group, this led to examination of the effects of fasting on
bacterial binding in relation to smoking.
Fasting is one of the environmental factors associated with peptic ulcers. Donderici
and colleagues noted that peptic ulcer complications were higher during Ramadan
than the periods before and after the fast [Donderici et al., 1994], It has been
claimed that long term fasting may contribute to healing of persistent ulcers by
improving the control of stomach secretion [Johnston and Wormsley, 1989].
Collection of BEC samples during the month of Ramadan provided an opportunity to
study the effect of fasting on binding of H. pylori to BECs in a non-patient group.
Fasting did not enhance bacterial binding or expression of Lewis antigens but there
were significantly higher levels of H type 2 for non-fasting donors compared cells
obtained when they were fasting. This could be related to lower saliva output
associated with fasting which is in agreement with previous observations in which
deprivation of salivary epidermal growth factor (EGF) significantly lowered levels
of salivary carbohydrate, lipids and covalently bound fatty acids, but showed higher
levels of protein content than normal [Sarosiek et al., 1988].
4.4.5 Conclusions
The evidence in this chapter indicated H type 2, Lea and Le^ can act as receptors for
H. pylori adhesion; therefore, the next step was to employ the affinity purification
method with synthetic blood group antigens [Saadi et al., 1994] to attempt to obtain
adhesins from H. pylori that bind H type 2 and Lewis antigens.
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Chapter 5
Isolation of a cell surface component of H. pylori that binds to H
type 2, Lewisa and Lewis^ blood group antigens.
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5.1 Introduction
Several surface components thought to be involved in binding of H. pylori to
epithelial cells have been identified (Table 5.1). While Le^ has been proposed to
act as a receptor for these bacteria [Boren et al., 1993], the surface component(s) that
bind to the antigen has not been identified. The results presented in Chapter 4 found
binding of H. pylori to Kato III or BEC could be inhibited by pretreatment with
monoclonal antibodies against H type 2, Lea or Le^ and that binding of H. pylori
correlated significantly with binding of monoclonal antibodies to H type 2 and Le^.
Both contain a terminal fucose in their structures which is not present on Lea (Figure
1.3).
Studies in which inhibition of bacterial binding by antibodies to the host cell
antigens is demonstrated are open to the criticism that the antibodies are binding to
an epitope near the site of the actual receptor, the inhibition observed being due to
stearic hindrance. Two methods were proposed to obtain additional evidence that H
type 2 and the Lewis antigens are receptors for H. pylori: direct binding of synthetic
blood group antigens (now available at a reasonable cost) to the bacteria; and
synthetic Lea has been used for affinity purification of adhesin(s) from S. aureus
[Saadi et al., 1994].
The aims of this section were: 1) to develop a direct attachment assay for binding of
biotinylated blood group antigens to whole cells of H. pylori; 2) to isolate surface
components of H. pylori that bind H type 2 or Lewis blood group antigens by
affinity purification; 3) to assess the ability of the component(s) obtained by affinity
purification to reduce attachment of the bacteria to epithelial cells; 4) to determine
what proportion of H. pylori isolated from local patients expressed the adhesin(s)
that binds the H type 2 and Lewis blood group antigens.
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Table 5.1





Evans et al., 1988 and 1993
25 kDa Haemagglutinin
NeuAc-lactose specific
Huang et al., 1992
59 kDa Haemagglutinin
specificity unknown
Huang et al., 1992
63 kDa Phosphatidylethanolamine Lingwood et al., 1993
60 Hela cells
specificity unknown
Fauchere and Blaser., 1990
Unknown Le^ blood group Boren et al., 1993
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5.2 Materials and Methods
5.2.1 Bacteria Strains and growth culture
H. pylori NCTC 11637 and 51 local patient isolates were cultured for 5 days under
the conditions described in (2.8.1).
5.2.2 Extraction of outer membranes
H. pylori NCTC 11637 was cultured on Campylobacter selective medium as
described (2.6.1). Outer membranes (OM) were obtained by the method of Blaser et
al. [1983]. Bacterial suspensions were washed 3 times in 0.01M Tris buffer (pH
7.4) then sonicated for 15 min (three 5 minutes intervals with a period for cooling
between each). The cells were centrifuged 1000 x g for 20 min. The supernatant was
collected and centrifuged at 100,000 x g for 60 min at 4°C and the resulting pellet
was treated with 5 ml of 1% sodium N-lauroylsarcosine solution (Sarkosyl) and
incubated for 20 min at 37°C. OM representing the Sarkosyl-insoluble fraction was
collected by centrifugation at 50,000 x g for 60 min at 4°C, resuspended in sterile
distilled water, freeze dried and stored at -20°C.
5.2.3 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) of OM
Outer membrane proteins (OMP) were separated by SDS-PAGE using the SDS-
discontinuous system with a Biometra-Minigel (Biometra, Wagen-Stieg, Gottingen,
Germany). Equal volumes of protein sample and sample buffer were mixed and
heated to 100°C for 5 min. Samples were applied to each lane and electrophoresis
performed at a constant voltage of 40 V through the stacking gel (5% acrylamide)
and at a constant voltage of 70 V through the resolving gel ( 10% acrylamide).
OMPs were visualised by staining with Coomassie brilliant blue (0.5%, w/v) in 25%
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(v/v) propan-2-ol + 10% (v/v) glacial acetic acid followed by destaning with 10%
(v/v) glacial acetic acid.
5.2.4 Purification ofOMP by affinity adsorption
Synsorb affinity adsorbent (1 mg/ml) (Chem Biomed Ltd., Edmonton, Alberta,
Canada; lot ASi-137) with Lea, Le^ or H type 2 covalently linked to the silica matrix
was swollen in universal containers in 2 ml of PBS (pH 7.2) for 2 h at room
temperature with continuous rotation. The beads were centrifuged at 50 x g for 5 min
and the supernatant removed. The OMP extracted from strain NCTC 11637 (65
|ig/ml) was added to the beads and incubated with continuous rotation overnight at
4°C then centrifuged at 50 x g for 5 min and the supernatant containing unbound
material was collected. The beads were washed three times with 5 ml of PBS and
the washings added to the unbound material. The bound material was eluted from
Synsorb beads by 2 ml of 2% ammonia in saline for 20 min with continuous rotation
at room temperature. The supernatant was recovered following centrifugation at 50
x g for 5 min. The beads were washed with 5 ml of PBS and centrifuged again. The
combined eluates were freeze dried and reconstituted in 300 p.1 distilled water
(Figure 5.1).
5.2.5 Dot blot assay
5.2.5.1 High salt buffer (HSB)
HSB was composed of PBS containing 1M NaCl and Tween 20 (0.5%, v/v) (DBH,
Poole, Dorset).
5.2.5.2 Substrate
The substrate contained 160 mg dioctyl sulfo-succinate (DONS) (Sigma), 49 mg
tetramethyl benzidine (TMB) in 12 ml of buffer composed of 24.3 ml 0.1 M citric
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acid (BDH), 25.7 ml 0.2 M Na2HP04 (BDH), 50 ml ethanol and 60 ml distilled
water. The mixture was placed in a water bath at 60°C for 30 min and activated by
adding 60 (Xl hydrogen peroxide (30% v/v) (Sigma) immediately prior to use.
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5.2.6 Dot blot of whole bacteria
A heavy bacterial suspension of H. pylori strain NCTC 11637 was made by
transferring several colonies with a wire loop from a subculture plate to a tube
containing 200 pi PBS and heated at 100°C for 60 min to inactivate catalase. The
nitrocellulose membrane (Gelman Sciences, Northampton) was cut into rectangles to
fit into split plates. Circles were drawn in pencil on the shiny side of the membrane.
The bacterial suspension (10 pi) was added to circles on rectangular strips of each
membrane which were to receive different treatments. As positive controls
monoclonal antibodies to Lea, Le^, Lewisx (Lex) (Serotec) and H type 2 were
added to the strips without bacteria in a similar manner. The strips were incubated
for 10 - 15 min at 37°C. Biotinylated Lea, Le^ , Lex or H type 2 (10 pi )
(Syntesome GmBh, Fine Biochemicals) diluted in HSB (100 pg mH) were added to
separate circles and incubated at 37°C for 1 hr. A washing stage in HSB followed
for 15 min and the fluid was discarded. The strips were immersed in tap water for 1
min and placed in HSB. HSB was discarded and streptavidin horseradish peroxidase
(HRP) (Sigma) (0.5 ml, 1.3 pg ml~l ) was added and incubated at 37°C for 1 hr.
After a final wash in HSB, 2 ml of the substrate (5.2.4.2) was added and incubated
with the strips at room temperature for 5 min for colour development. The reaction
was stopped by washing with tap water.
5.2.7 Dot blot of outer membrane proteins
The same method as described in (5.2.6) was used for the outer membranes.
5.2.8 Binding of biotinylated blood group antigens to whole bacteria
An assay for detection of biotinylated blood group antigens to whole cells of H.
pylori was developed. Bacteria were grown for 5 days under the conditions
described earlier (2.6.1). A heavy suspension in PBS was heated at 100°C for 60
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min then centrifuged at 1000 x g for 20 min. The pellet was resuspended in coating
buffer (2.1.1) and standardised by optical density to a total count of 3.2 x 10^
determined by correlation of OD at 540 nm with direct microscopy (2.6.3).
Batches of 96 well microtitre plates were coated with 100 pi of bacteria and
incubated overnight at 4°C. The plates were washed with washing buffer (2.1.3),
blocked with blocking buffer (2.1.4) and incubated at room temperature for 20 min.
The blocking buffer was removed and the plates washed with washing buffer.
Biotinylated Lea, Le^, Lex or H type 2 antigens diluted in blocking buffer to 100 jig
ml~l were added to the wells and incubated at 37°C for 60 min. The plates were
then washed 6 times with washing buffer. Streptavidin-HRP (100 pi, diluted to 1.3
|ig ml~l in blocking buffer) (Sigma) was added to the plates and incubated for 60
min at room temperature then washed 6 times in washing buffer. The substrate (100
pi ) (2.1.6) was activated by 40 ml H2O2 (30% v/v) immediately before use and
added to each well. The colour change was stopped after 10 - 20 min by adding 100
pi of H2SO4 (2.1.7) (Fig 5.2). The optical density at 490 nm was determined by an
ELISA reader (Dynatech) and corrected by subtracting the OD of the corresponding
blank well containing bacteria, streptavidin-HRP and substrate.
5.2.9 Binding of biotinylated blood group antigens to the component isolated
by affinity adsorption
An assay for detection of binding of biotinylated blood group antigens to affinity
purified protein was developed. The same protein concentrations of unbound
supernatant and the proteins eluted from the Synsorb beads were used to coat wells
of a 96 well microtitre plate (100 pi of 10 pg ml"1 protein) and incubated overnight
at 4°C. The plates were treated as described above (5.2.7).
5.2.10 Inhibition of binding ofH. pylori to Kato III cells
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A heavy suspension of the bacteria was prepared in PBS and washed three times by
centrifugation at 1000 x g for 20 min. The bacteria were labelled with FITC and
adjusted to 3.2 x 10^ as described in 4.2.2.
The material eluted from Synsorb H type 2, Lea or Le^ (adhesin) was resuspended in
PBS and 200 pi was added to 200 pi of the Kato III cell suspension . The cells were
incubated at room temperature for 60 min, washed twice in PBS by centrifugation at
600 x g for 10 min and the labelled bacteria (200 pi, 300 bacteria /cell) added to each
sample. Controls were Kato III cells incubated with PBS but no protein eluate. The
samples were incubated at 37°C for 60 min with gentle shaking (100 rpm) in an
orbital incubator (Gallenkamp) then washed twice in PBS at 600 x g for 10 min.
The washed cells were resuspended in 150 pi of PBS and fixed with 100 pi of 1%
buffered paraformaldehyde. They were stored in the dark at 4°C until analysed by
flow cytometery (Coulter EPICS-XL, UK). The binding index (BI) for each sample
was calculated from the percentage of the cells with fluorescence greater than the
background multiplied by the mean fluorescence of the positive population. The
percent inhibition was calculated by the formula used in chapter 4.
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O/N = over night RT = room temperature
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5.3 Results
5.3.1 Dot blot of whole cells bacteria and OM
Dot blot assays with whole cells of H. pylori NCTC 11637 or equivalent amounts of
the OM extract appeared to bind more biotinylated H type 2 as judged by the colour
intensity of the blot. Lea appeared to bind the least and Le^ gave an intermediate
colour. No colour was observed with biotinylated Lewisx. The quality of the
photographs were not sufficient to demonstrate the differences observed; therefore a
quantitative spectrophotometric assay was developed.
5.3.2 Binding of biotinylated blood group antigens to H. pylori
Direct attachment of biotinylated blood group antigens to H. pylori NCTC 11637
was examined with different concentration of bacteria 3.5, 1.75, 0.87 and 0.44 x
10&. Figure 5.3 showed the dose response effect of bacterial concentration on
binding of the blood group antigens. Further experiments were carried out with
bacteria adjusted to 3.2 x 10^.
Figure 5.4 shows the mean of six experiments in which binding of biotinylated
blood group antigens to H. pylori strain NCTC 11637 was assessed in microtitre
plates. The highest optical density readings were observed with H type 2 followed by
Le^ and the lowest values with Lea. By the t-test for two groups test, OD values for
H type 2 was significantly higher than Le*5 (P< 0.02), Ft type 2 was significantly
higher than Lea (P< 0.003), Le^ significantly higher than Lea (P< 0.002), H type 2
was significantly higher than group A and group B (p < 0.02 and p < 0.03
respectively) and Le^ was significantly higher than group A and group B (p < 0.03
and p < 0.01 respectively) Sequential culture (5 subcultures) of the strain did not














Bacteria concentration x 10^
Figure 5.3 Dose response of bacterial binding to biotinylated blood group antigens
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0.201
Figure 5.4. Mean of six experiments to assess binding of biotinylated blood group
antigens to H. pylori NCTC 11637.
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5.3.2.2 Binding of biotinylated blood group antigens to OMP
Attachment of the blood group antigens to OMP extracted from H. pylori NCTC
11637 was assessed by the same assay with 4 different concentration of OMP 5, 2.5,
1.25 and 0.6 pg ml"*. The results showed a dose dependent response; the highest
optical density readings were observed at 5 pg ml" 1 protein. The highest optical
density readings were observed with H type 2 followed by Le^ and the lowest values
with Lea (Figure 5.5).
5.3.3 Isolation of the adhesin by affinity adsorption
SDS-PAGE (10% acrylamide) of the Sarkosyl-insoluble outer membrane protein of
NCTC 11637 stained with Coomassie blue showed three major bands migrating at
approximately 30, 45 and 61 kDa; additional bands were seen at 54, 75, 110 and 142
kDa. The protein concentration of the original OMP extract was 65 pg ml" * (track
1). The protein concentrations of the material eluted from Synsorb H type 2, Lea and
Leb were 15 pg ml"*, 5 pg ml"* and 10 pg ml"* respectively. The material eluted
from Synsorb H type 2, Synsorb Lea and Synsorb Le*> migrated as a band at
approximately 61 kDa (figure 5.6).
5.3.4 Inhibition of bacterial binding by the adhesin
Binding of H. pylori NCTC 11637 to Kato III cells was inhibited with the material
eluted from Synsorb H type 2, Lea or Le*\ The percentage inhibition of bacterial
binding was 74% with the material eluted from Synsorb H type 2, 64% material
eluted from Lea and 67% with material eluted from Le*> (figure 5.7). This reflected
the protein concentration of the individual elutes.
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Outer membrane concentration (jig/ml)
Figure 5.5 Dose response of binding of outer membrane protein to biotinylated
blood group antigens assessed by microtitre plate assay.
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Figure 5.6 Coomassie brilliant blue stained SDS-PAGE gel (10%) of Sarkosyl
insoluble membrane (track 4), material eluted from Synsorb Lewis'3 (track 3),
Synsorb Lewisa (track 2) and Synsorb H type 2 (track 1).
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B Synsorb H type 2
0 Synsorb Le'1
0 Synsorb Lea
Figure 5.7 Inhibition of binding of H. pylori NCTC 11637 to Kato III cells
following treatment with material eluted from Synsorb beads (mean of 4
experiments)
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5.3.5 Binding of biotinylated blood group antigens to the adhesin isolated by
affinity adsorption
Binding of the biotinylated blood group antigens to OMP, purified adhesin and
unbound material was compared at the same protein concentration (10 pg ml~l) by
the spectrophotometric assay. The same patterns were obtained with dot blot and
microtiter assays; H type 2 gave the highest OD or colour intensity, Le^ was
intermediate and Lea the lowest. The purified adhesin bound higher levels of the
blood group antigens compared with OMP and the lowest values were observed with
unbound material at the same protein concentration (figure 5.8).
5.3.6 Reproducibility of test
The 51 local patient isolates were tested on 2 occasions, strain NCTC 11637 was
included in each experiment as a control and Lex was used as negative control. All
isolates bound H type 2, Le^ and Lea but not Lex.
5.3.7 Patterns of binding of biotinylated blood group antigens to local H.
pylori isolates
Among the 51 patient isolates, there were four patterns of attachment of the
biotinylated oligosaccharides (Table 5.2). For the majority of the strains, the pattern
was similar to that of NCTC 11637, the highest OD values were observed with H
type 2, the lowest with Lea and Le^ was intermediate. There were 5 isolates for
which the OD values obtained with Lea were greater than or equal to those for Le^








Figure 5.8 Mean of two experiments of to detect binding of biotinylated blood group
antigens to adhesin of H. pylori NCTC 11637 obtained by synthetic Synsorb beads
compared with equivalent concentration (10 pg mH) of OMP and unbound
materials.
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Table 5.2 Binding of biotinylated blood group antigens to H. pylori isolated from
patients attending the gastroenterology clinic.
ABH antigens H. pylori Blood group O Non-secretor
isolates %
n = 51 n % n %
H2>Leb>Lea 37 72.5 27/37 72.9 17/37 45.9
Leb > H2 > Lea 7 13.7 4/7 57 3/7 42.8
Lea>Leb 3 5.9 1/3 33.3 2/3 66.6
Lea = Leb 4 7.8 0/4 0 2/4 50
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5.4 Discussion
5.4.1 Development of an assay for direct binding of blood group antigens to H.
pylori
The first aim of this part of the study was to develop a method to demonstrate direct
binding of the blood group antigens proposed to act as receptors for H. pylori. The
microtitre spectrophotometric assay was developed to provide a rapid, quantitative
and reliable method for screening isolates to determine what proportion of them
bound the blood group antigens. All steps and working concentrations were adjusted
to obtain the maximum reading while keeping the OD values for negative controls
low, including the optimal bacteria concentration in the coating buffer which leads to
the formation of a monolayer of bacteria on the surface of the wells. The technique
for coating the bacteria is easy to perform and to standardise. The method can be
applied to a wide range of H. pylori isolates. The OD values complemented the
colour intensity observed in the dot blot assay which could not be quantified.
5.4.2 Attachment of biotinylated blood group antigens to H. pylori
All the 51 patient isolates tested bound H type 2, Lea, Le^ but not Lex, 4 patterns
were observed. The majority (72%) were similar to that of NCTC 11637 H type 2 >
Leb > Lea. There was no significant association with disease, ABO group or
secretor status. The majority of the isolates exhibited a binding pattern similar to
that ofNCTC 11637. This suggests that all the strains tested express the adhesin that
binds the fucose containing blood group antigens.
5.4.3 Isolation of a 61kDa protein by affinity purification
The results in chapter 4 indicated that the putative receptors H type 2, Lea and Le^
are present on the gastric cells. The SDS-PAGE analysis of the OMPs of H. pylori
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NCTC 11637 are in agreement with previous findings by other groups; there were
three major OMPs bands at approximately 61, 54 and 30 kDa [Newell., 1987; Czinn
et al., 1989 and Drouet et al., 1991]. The 61 kDa protein was obtained by affinity
adsorption with synthetic Synsorb H type 2, Lea or Le^ with the greatest amount
eluted from H type 2, the lowest from Lea and an intermediate amount from Le^.
5.4.4 Inhibition of bacterial binding by pretreatment of epithelial cells with
the adhesin
Pre-treatment of human cells with the 61 kDa protein obtained by affinity
adsorption with synthetic Synsorb H type 2, Lea or Le^ showed inhibition of
binding of H. pylori NCTC 11637; and, the ability to inhibit binding reflected the
protein concentration in the eluates from the three different Synsorb blood group
antigen preparations. The percentage inhibition was greatest for the protein obtained
from H type 2 followed by that eluted from Le^. The least inhibition was observed
with the protein obtained from Lea which was most probably related to the amount
of protein eluted from the different Synsorb antigens.
Immunoelectron microscopic studies indicated that a 61 kDa heat shock protein is
nearly exclusively associated with the outer surface of the OMP [Eschweiler et al.,
1993], The H. pylori urease lacks a leader sequence and it was suggested that close
association with the 61 kDa protein might support the transportation, stabilisation
and folding of the urease [Eschweiler et al., 1993]. Monoclonal antibodies raised
against 60 kDa (61 kDa) heat shock protein effectively inhibited binding of the
bacteria to cells [Hamid-Reza et al., 1996],
Fauchere and Blaser [1990] have described loosely associated surface material of H.
pylori that contain both urease and adherence activities. This adhesin bound to Elela
cells and was not affected by neuraminidase treatment ; selective removal of sialic
acid or preincubation of the bacteria with sialylated glycoprotein did not reduce
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bacterial binding [Fauchere and B laser, 1990], Other work suggested that the H.
pylori receptor on the gastric surface mucosa cells contains fucose [Falk et al.,
1993], Boren et al. [1993] found no strong evidence for the involvement of blood
group antigens other than Le^ in binding of H. pylori in their model system. They
used tissue sections and assessed binding microscopically, but this study examined
cells in suspension and detected binding by flow cytometry and different monoclonal
antibodies.
5.4.5 Conclusion
The results in this chapter demonstrated direct binding of H type 2 and Lewis
antigens to whole bacterial cells, OMP or the protein isolated by affinity purification.
The results complement those obtained in chapter 4 which indicated that monoclonal
antibodies to H type 2, Le^ and Lea inhibited bacterial binding. The intensity noted
with the dot blot assay paralleled the results of the microtitre assays for NCTC
11637 which was H type 2 > Le^ > Lea. These results also reflected the amounts of
the 61 kDa protein obtained by affinity purification with synthetic H type 2, Le^ and
Lea. If binding of oligosaccharides in vitro reflect their interactions with the
bacteria in vivo, the greater binding of Le^ compared with Lea might more








While epidemiological studies indicated that individuals of blood group O or non-
secretors are over represented among patients with peptic ulcers, among those with
gastric carcinoma there are significantly more of blood group A [summarised by
Mourant et al., 1978]. These finding indicate factors other than presence of the
bacteria, perhaps the host immune or inflammatory responses contributes to
development of disease associated with H. pylori infection.
Epidemiological studies suggest chronic infection with H. pylori is associated with
ischaemic heart disease (IHD) [Mendall et al., 1994; Glynn, 1994; Miragliotta et al.,
1994; Martin-de-Argila et al., 1995]. Patel and colleagues reported that H. pylori
infection might contribute to increased risk of IHD by increasing fibrinogen levels
among patients with H. pylori infection [Patel et al., 1994] as these bacteria produce
a tissue factor with procoagulant like activity which can convert fibrinogen to fibrin
[Miragliotta et al., 1989]. Plasma fibrinogen is an independent risk factor for IHD
and cardiovascular disease [Kannel et al., 1987; Qizibash et al., 1991]. The increase
of plasma fibrinogen produced by hepatocytes is mediated mainly by interleukin-6
(IL-6) produced by monocytes and macrophages [Akira and Kishimoto, 1992]
In most persons infected with H. pylori there is an increase in chronic inflammatory
cells in the lamina propria including lymphocytes, monocytes, eosinophils and
plasma cells [Blaser, 1992], Cytokine proteins produced by various cell types are
important mediators of inflammatory responses. Local increases in IL-6 have been
associated with bacterial infections both at mucosal [ De Man et al., 1989] and non-
mucosal sites [Helfgott et al., 1989; Bhardwaj et al., 1989]. The supernatants of
gastric mucosal biopsy specimens from patients with H. pylori gastritis had high
levels of tumour necrosis factor alpha (TNF) and interleukin 6 (IL-6) [Crabtree et al.,
1991].
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Chronic infection and inflammation have been recognised as risk factors for a
variety of human cancers and it has been proposed that active oxygen species such as
superoxide anion, hydrogen peroxide and hydroxyl radical generated in inflammed
tissues can cause injury to target cells and also damage DNA. These responses
could contribute to tumour development [reviewed by Ohshima and Barsch, 1994],
There is now increasing evidence to suggest that nitric oxide (NO) and its
derivatives produced by activated phagocytes might also play a role in the multistage
carcinogenesis process [reviewed by Ohshima and Barsch, 1994], Nitric oxide also
inhibits platelet and leukocyte adhesion to endothelial cells as well as mediating
platelet plug disaggregation [Radomski et al., 1987; Moncada et al., 1988;
Gryglewski et al., 1988; Bath et al., 1991]
The aims of this part of the study were: 1) to determine if there was evidence for H.
pylori infection among IHD deaths in the local population and 2) to compare
inflammatory responses (IL-6, TNF or NO) from human buffy coats of blood group
O and group A exposed to H. pylori antigens.
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6.2 Material and methods
6.2.1 Antigen preparation
Antigen preparations for the H. pylori ELISA were basically performed according to
the method of Newell (1986). H. pylori NCTC 11637 was cultured as described in
chapter 2. Bacterial cells were harvested and washed twice in 5 ml of distilled water
and suspended in 0.2 M glycine hydrochloride buffer (pH 2.2) at a concentration of
0.1 g of cells to 2.5 ml of buffer. The suspension was gently shaken for 15 min at
room temperature and then centrifuged at 11 000 x g for 15 min at 4°C. The
supernatant was dialysed overnight against sterile distilled water at 4°C.
6.2.2 Detection of antibodies to H. pylori in autopsies
Batches of 96 well microtitre plates were coated with 100 (il of 5jxg mH of H.
pylori NCTC 11637 antigens and incubated overnight at 4°C as described in 3.2.6.
The plates were washed with washing buffer and blocked with blocking buffer.
Serum from autopsy samples diluted 1/100 in blocking buffer were added to the
wells for detection of IgG and incubated at 37°C for 60 min then washed with
washing buffer. HRP-anti-human IgG (Sigma) diluted 1/200 in blocking buffer were
added to the plates and incubated for 60 min at room temperature. The assay was
continued in the same way as the whole cell ELISA for determination of antibodies
in patients serum (3.2.7) . The assays for all autopsy samples were examined at the
same time under the same conditions for specific IgG.
6.2.3 Collection of human peripheral blood monocytes
Buffy coats (50 ml) were obtained from the Scottish National Blood Transfusion
Service and diluted 1: 2 using sterile PBS under aseptic condition. Diluted blood (15
ml) was layered carefully on histopaque (5 ml) (Sigma, Poole, UK) in sterile plastic
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centrifuge tubes and centrifuged for 30 min at 300 x g. Mononuclear leukocytes
were collected from the interface, and washed twice with pyrogen free PBS or
DMEM (Gibco) then resuspended in DMEM with 10% human serum, each
individual buffy coat with it's respective serum.
6.2.4 Determination of ABO blood groups
The ABO blood group of the donors was determined from blood specimens by slide
agglutination with monoclonal anti-A and anti-B antibodies (2.3)
6.2.5 Stimulation of human monocytes
Buffy coats were resuspended in DMEM with 10% human serum with streptomicin
(200 p.g ml"1) and penicillin (100 IU ml"1) and adjusted to 2 x 10^ ml-1. Cells (500
pl/well) were placed in 24 well tissue culture plates. They were then mixed with 500
p.1 of different concentrations of whole bacteria, OMP or purified adhesin of H.
pylori NCTC 11637 suspended in DMEM containing 10% FCS without antibiotics
were added to the plates. Controls contained only medium with 10% FCS and cells.
The plates were incubated in a 37°C in a humidified 5% C02 incubator. At
different intervals, the supernatants were collected in sterile tubes, centrifuged at 300
x g for 10 min, collected and used directly to estimate the amount of TNF, IL-6 or
NO.
6.2.6 ELISA for detection of IL-6
IL-6 levels were measured with a solid phase ELISA. Microtiter flat-bottomed
plates (96 wells) were coated with 100 p.l/well of 0.5 jig ml"1 mouse monoclonal
antibody specific for IL-6 (R&D Systems, Abingdon, UK) in coating buffer (2.1.1)
and incubated over night at 4°C. They were washed 6 times with washing buffer
(2.1.3) and 100 pl/well of blocking buffer (2.1.4) added and incubated for 30 min
then removed. Supernatant samples (100 p.1) were added to duplicate wells.
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Dilutions of recombinant human IL-6 standard (R&D) in blocking buffer were used
as positive controls. The plates were incubated for 2 hr at 37°C with continuous
shaking. The plates were washed 6 times and 100 pi of goat polyclonal anti-human
IL-6 (R&D) was added to the wells and incubated for 2 hr at 37°C with continuous
shaking. After the plates were washed 6 times, 100 pi of HRP conjugated donkey
anti-goat IgG were added to the wells for 1 hr at 37°C with continuous shaking then
washed 6 times with washing buffer. The substrate (100 pi) (2.1.6) was activated
by 40 ml H2O2 (30% v/v) immediately before use and added to the wells. The
colour change was stopped after 10 - 20 min by adding 100 pi of H2SO4 (2.1.7).
The optical density at 490 nm was determined by an ELISA plate reader (Dynatech)
and corrected by subtracting the OD of the corresponding blank well containing each
of the components except the supernatant from the cells. The amount of IL-6 in each
sample was determined relative to the human IL-6 standard curve and results were
expressed in ng ml"l.
6.2.7 TNF bioassay
The L929 mouse fibroblast cell line was obtained from the European Collection of
Animal Cell Cultures (ECACC, Salisbury, UK) and cultured in growth medium
DMEM containing 10% FCS. L929 cells were dislodged by 0.1% trypsin (w/v)
(Gibco, Paisley, UK) to avoid cell clumping and washed with DMEM by
centrifugation at 300 x g. They were resuspended in growth medium and adjusted to
3.0 x 105 ml-1. Cells (100 pi ) were placed in flat-bottomed 96 well tissue culture
plates and incubated at 37°C in a humidified incubator containing 5% CO2 for 24 hr.
The growth medium was discarded and replaced with 100 pi / well of test
supernatants diluted 1: 1 in assay medium (DMEM containing 5% FCS, 1 mM L-
glutamine and 2 pg ml"1 actinomycin D (Sigma, Poole, Dorset). The supernatants
were tested in triplicate. Series of two fold dilutions of a standard of recombinant
human TNF (NIBSC, Hertfordshire, UK) in assay medium containing 1 pg ml"1
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actinomycin D. The concentrations which ranged from 2 to 1000 IU ml"1 were
added to wells in triplicate. TNF standard was used in every plate. In each assay, 6
wells with 100 pi of assay medium containing 1 pg mL"1 actinomycin D were
included as controls and another 6 wells without L929 cells were included in each
plate as blanks. All were treated identically to the test samples. Plates were then
incubated at 37°C in a humidified incubator containing 5% CO2 for another 24 hr.
The supernatant in each well was removed and replaced with 50 pi crystal violet
(0.5% w/v in 20% methanol in distilled water which had been filtered through
Whatman no 1 filter paper. After 2 min, plates were washed with tap water and
allowed to dry. Each well received 50 pi 20% acetic acid to solubilise the stained
cells. Any air bubbles were removed and optical density was measured at 570 nm
with a microplate reader (MR 700 Dynatech Laboratories). The amount of TNF in
each sample was determined relative to the TNF standard curve and results were
expressed in IU ml"1.
6.2.8 Nitric oxide assay
Nitric oxide production was assessed by measuring nitrite, a stable metabolic
product of NO, in supernatants of the mononuclear phagocytes [Zhang et al., 1994],
Griess reagent a 1:1 (v/v) mixture of 0.3% N-1 naphthyl ethylenediamine
dihydrochloride (Sigma) and 1% sulfanilamide (Sigma) in 5% H2PO4 was added to
96 well tissue culture plates at 100 pl/well. Equal volumes of culture supernatants
were added to the Griess reagent and incubated for 10 min at room temperature. The
absorbence was determined on a MR 700 microplate reader (Dynatech Laboratories)
at 570 nm. Results were compared to a standard curve of dilutions of sodium nitrate
prepared for each experiment.
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6.3 Results
6.3.1 Levels of IgG antibodies to H. pylori in autopsy specimens
Among 70 patients with no history of gastritis, peptic ulcer or gastric cancer, there
were 37 patients whose primary cause of death was IHD. Diagnosis of IHD was
made on the basis of evidence of narrowing or occlusion of one or more of the
coronary arteries due to atheroma and/or thrombosis. In addition there could also be
evidence of previous ischaemic damage to heart muscle, usually in the form of
fibrosis. Serum samples from 33 age and sex matched individuals whose recorded
cause of death was accidental were used as controls.
All autopsy serum samples were diluted 1/100 and screened for specific IgG for H.
pylori. There were higher IgG levels specific for H. pylori in sera from IHD deaths
(mean OD = 1.001) compared with those obtained with sera from accidental deaths
(mean OD = 0.770) (p < 0.06). Detailed examination of the autopsy findings
revealed that 8 of the accident victims had significant evidence of heart disease,
although this was not the primary cause of death. Re-analysis of the results in which
the accident victims with evidence of heart disease were included in the IHD group
found significantly higher levels of IgG to H. pylori among the IHD group (mean =
1.010) compared with the accident group (mean = 0.690)(p < 0.009) (Table 6.1)
Assessment of the data by age found that the levels of IgG to H. pylori were higher
among the IHD group who died earlier (the 40 - 59 years age range). This difference
was not observed among samples from the two groups in the age range > 60 years
(Figure 6.1).
There were no significant differences observed for specific IgG levels for H. pylori
in autopsy serum samples from IHD cases compared with accident cases with
references to blood group (Table 6.1).
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6.3.2 The effect of incubation time on release of TNF, IL-6 and nitric oxide
from human huffy coat
The IL-6 and TNF production was examined by stimulating human monocytes (2 x
1C)6) with OMP of H. pylori NCTC 11637 at a concentration of 1.9 (ig mH at 4, 8,
18, 42, 66 and 90 hr. The results showed that TNF was released at 4 hr after
stimulation and the amount detected increased progressively until 18 hr when it
started to decrease. IL-6 was detected at 4 hr after stimulation but increased
progressively until 42 hr when it started to decrease. Nitric oxide was released 42 hr
after stimulation with the highest OD obtained at 66 hours (figures 6.2, 6.3 and 6.4)
6.3.3 IL-6 released in response to H. pylori antigens
6.3.3.1 The effect of purified adhesin and OMP on release of IL-6
IL-6 release was assessed for different concentrations of whole cells, purified
adhesin and OMP. The results were dose dependent. Release of IL-6 stimulated
with purified adhesin or OMP at concentrations of 1.87, 3.75, 7.5 and 15 pg ml""!
was increased with increasing concentrations of antigen. Higher levels of IL-6 were
obtained with purified adhesin compared with equivalent amounts of OMP with cells
from 3 different donors (paired two-tail t-test). There was a significant release of IL-
6 in response to adhesin compared with OMP (P<0.03) (Figure 6.5).
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Table 6.1 Comparison of optical density of specific IgG for H. pylori with reference
to blood group and cause of death, A) before and B) after accident individuals were
screened for signs of heart disease (SE = standard error) P value assessed by Mann
Whitney U test
ACCIDENT IHD
n = 33 n = 37
A) mean SE mean SE P value
Group A (n = 43) 0.75 0.11 0.97 0.11 P<0.1
Group O (n = 27) 1.001 0.16 1.04 0.12 P<0.8
All cases (n = 70) 0.770 0.08 1.001 0.08 P<0.06
ACCIDENT IHD
n = 25 n = 45
B) mean SE mean SE
Group A (n = 43) 0.72 0.12 0.97 0.11
Group O (n = 27) 0.900 0.23 1.06 0.10
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Figure 6.1. Levels of IgG to H. pylori assessed by age and evidence of IHD
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Figure 6.2 Mean of two experiments to assess the effect of incubation time on
release TNF from buffy coats stimulated with OMP (1.9 jig ml'l) of H. pylori
NCTC 11637
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Figure 6.3 Mean of two experiments to assess the effect of incubation time on
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Figure 6.4 Mean of two experiments to assess the effect of incubation time on








Figure 6.5 Mean of IL-6 released from human buffy coats of 3 individuals
stimulated for 42 hours with different concentrations of whole cell, OMP or purified
adhesin of H. pylori NCTC 11637.
* proteins (Xg ml" 1 ** bacteria x lO^ml"!
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6.3.2.2 The effect of blood group on release of IL-6
Human buffy coats of 16 different individuals released IL-6 in response to
stimulation with 1.9 fig/ml of purified adhesin. Those from individuals of blood
group O (n = 8) had significantly higher IL-6 levels (mean 4.69 ng ml~l) compared
with IL-6 released from buffy coats obtained from blood group A individuals (n = 8)
(mean 2.97 ng ml~l) (Mann-Whitney U test, P< 0.05) (Figure 6.6).
6.3.3. TNF released in response H. pylori antigens
6.3.3.1 The effect of purified adhesin and OMP on release of TNF
TNF release in response to different concentrations of whole cell, purified adhesin
and OMP was examined with buffy coats from 3 different individuals. At 8 hr
following stimulation, the release of TNF from buffy coats in response to increasing
concentrations of the purified adhesin or OMP was dose dependant. By the paired
two-tail t-test, there was significantly increased release of TNF from the cells in


















Figure 6.6 IL-6 released from cells of 8 group O and 8 blood group A donors
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Figure 6.7 Mean TNF released from buffy coats of 3 different individuals stimulated
for 8 hours with different concentration ofwhole cell, OMP or purified adhesin of H.
pyloriNCTC 11637.
* proteins pg ml" 1 ** bacteria xlO^ml"!
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6.3.3.2 The effect of blood group on release of TNF
TNF released from human buffy coats of blood group O (n = 8) and blood group A
(n = 8) donors in response to purified adhesin was assessed. The results showed that
the mean TNF released from cells of blood group O individuals (262 IU ml""!) was
significantly higher than that from cells of blood group A individuals (190 IU ml"*)
(Mann-Whitney U test, P<0.05) (Fig 6.8).
6.3.4. Nitric oxide release in response to H. pylori antigens
6.3.4.1 The effect ofOMP, purified adhesin and whole cell bacteria on release
of nitric oxide
The assay detected nitrite at levels ranging between 1 to 100 p mol'l. Because some
of the OD values in the experiments were below the lower limits of the standard,
results are expressed as OD rather then p moH. Nitric oxide released in response to
different concentrations of purified adhesin, OMP (1.25, 2.5, 5 and 10 pg ml~l) or
whole bacteria (0.625, 1.25 and 2.5 x 10^ bacteria ml~l) was assessed. In
experiments with cells from 4 different donors, there was a dose dependent effect
with decreased nitric oxide levels detected at 66 hr with increasing concentrations
of the purified adhesin, OMP or whole bacteria. The levels of nitric oxide were
higher for cells exposed to concentrations of whole bacteria compared with cells
exposed to purified adhesin or OMP (Figure 6.9). In another experiment, cells from
3 different individuals were stimulated with a broader range of concentrations of
adhesin. A similar pattern of nitric oxide levels was observed in the range of
concentrations tested previously, but there was a biphasic pattern observed with the
broader range of concentrations tested (figure 6.10).
6.3.4.2 The effect of blood group on release of nitric oxide
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There were significantly higher levels of nitric oxide released from buffy coats of
blood group O individuals (n = 8) stimulated with whole bacteria at 2.5 x 10^
bacteria mH for an incubation time of 66 hr compared with blood group A (n = 8)
individuals . The mean optical density for blood group O individuals was (0.105)
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Figure 6.8 TNF released from 8 blood group O and 8 blood group A buffy coats

















Figure 6.9 Mean nitric oxide released from buffy coats of 4 individuals stimulated
for 66 hours with different concentrations of purified adhesin , OMP or whole cells
of H.pylori NCTC 11637.

















Figure 6.10 Nitric oxide released from buffy coats of 3 donors stimulated for 66
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Figure 6.11 Nitric oxide released from 8 blood group O and 8 blood group A buffy
coats stimulated with whole H. pylori NCTC 11637 (2.5 x 10& ml~l) for 66 hours.
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6.4 Discussion
The results are discussed with references to the objectives set out in the introduction.
6.4.1 IgG antibodies to H. pylori in relation to IHD
Most serological studies on H. pylori have been qualitative rather than quantitative.
The level of IgG antibodies to H. pylori correlated with the density of antral
colonisation by the bacteria and also with the degree of gastritis of the antrum
[Kreuning et al., 1994], The results obtained with sera from IHD deaths and
accident victims are in agreement with epidemiological studies which suggested that
chronic infection with Helicobacter pylori is associated with coronary heart disease
(IHD) [Mendall et al., 1994; Glynn, 1994; Miragliotta et al., 1994; Martin-de-Argila
et al., 1995]. In a case control study, Mendall and colleagues found that
seropositivity to H. pylori conferred a twofold risk of coronary heart disease
[Mendall et al., 1994], Morgando and colleagues observed an increase in the risk of
myocardial infarction at younger ages for patients with H. pylori infection as judged
by presence of antibodies in the blood [Morgando et al., 1995]. Although the
differences in levels of IgG for the younger age groups (40 - 59 years) were not
significant, this supported the finding by Morgando et al., [1995].
The advantage of using autopsy specimens is that evidence of asymptomatic heart
disease can be taken into consideration in the analysis of the results. The cases of
IHD examined were unexpected deaths which might indicates these were more
severe attacks which resulted in death. Epidemiological studies of IHD identified
an association between blood group A and myocardial infraction and also with
thrombosis [summarised by Mourant et al., 1978]. The opposite was observed in
this study, there were more blood group O individuals who died from of IHD
compared with group A but this was not significant. A similar trend was observed in
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the one study reported in which postmortem material was examined [reviewed by
Mourant and Kopec, 1978]. These studies need to be expanded to examine larger
numbers of autopsy samples and to compare these results with age and sex matched
individuals who survived their first heart attack.
H. pylori isolated from biopsy specimens can coagulate blood by stimulating
mononuclear cells. Following bacterial stimulation, mononuclear leukocytes
produce a tissue factor with procoagulant-like activity which, through the extrinsic
pathway of blood coagulation, converts fibrinogen into fibrin. This is suggested to
contribute to the pathogenesis of coronary heart disease [Miragliotta et al., 1994].
The effect of H. pylori gastritis on markers of inflammation such as fibrinogen
concentration, circulating leukocyte count, C reactive protein and sialic acid
concentration can be mediated via certain cytokines including TNF and IL-6.
Concentration of both these mediators are increased in the gastric mucosa of H.
pylori -infected patients [Crabtree et al., 1991].
6.4.2 Inflammatory responses ofmonocytes of blood group A and O donors
The proinflammatory cytokines, (TNF, IL-1, IL-6 and IL-8) are a class of
endogenous proteins that exert important influences on immune, haematological and
metabolic responses to injury [Fong et al., 1990]. They are active at low
concentrations and are produced by a variety of cells, including lymphocytes,
monocytes and neutrophils [Arai et al., 1990]. A previous study of cytokines
released from human buffy coats stimulated by H. pylori porins, showed release of
various cytokines obtained with different porin concentrations. These results
suggested that the surface components of H. pylori were able to induce a series of
inflammatory responses [Tufano et al., 1994], The purified adhesin that binds H
type 2 and Lewis antigens (chapter 5) was able to stimulate human buffy coats to
release TNF, IL-6 and NO. TNF and IL-6 were detected at 4 h after the stimulus
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and increased progressively until 18 h when TNF started to decrease. IL-6 levels
increased progressively until 48 hr and then started to decrease. Detection of the
cytokines was dose dependent with increasing TNF and IL-6 production observed
with increasing concentration of whole bacteria, OMP and adhesin, suggesting that
purified adhesin might play an important role in inflammatory responses in the
pathogenesis of H. pylori infection as well as adherence.
Nitric oxide has been implicated in a number of physiological and
pathophysiological functions in the gut. Decrease in gastric mucosal blood flow has
been identified as a prerequisite to the development of acute erosions and stress
ulcers [Mersereau and Hinchey, 1973]. Nitric oxide synthesis has been detected in
the gastric mucosa and appears to play a role in protecting it during physiological
stress by acting as an endogenous vasodilator supporting mucosal blood flow [Stark
and Szurszewski, 1992; Whittle et al., 1992].
6.4.3 Factors contributing to gastroduodenal disease
Development of more serious gastroduodenal disease might be related to infection
with ulcerogenic or carcinogenic strains of H. pylori [Blaser, 1994; Xiang et al.,
1995]. An increased prevalence of antibody against Cag A has been reported in
both peptic ulcers disease and gastric cancer patients [Tummuru et al., 1993;
Crabtree et al., 1993]. Studies using polymerase chain reaction amplification and
DNA hybridization to probe for the presence of CagA in clinical isolates were not
significantly associated with duodenal disease [Owen et al., 1994]. Hazell and
colleagues in a study of an Australian population reported the prevalence of
antibodies against CagA in the duodenal ulcer group was higher than that found in
the control group; however, in a Chinese population, no significant difference was
found between the prevalence of antibodies to the CagA antigen in asymptomatic
subjects compared with gastric cancer patients [Hazell et al., 1996]. Analysis of the
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antibody responses to other H. pylori antigens such as the 30 kDa and 45 kDa
antigens identified an association with gastric cancer [Hazell et al., 1996] and cluster
analysis of the Western blot profiles showed that sera from gastric cancer patients
reacted with almost all the major antigens of H. pylori tested [Hazell et al., 1996],
Chronic infection and inflammation have long been recognised as risk factors for a
variety of human cancers. Nitric oxide and other oxygen radicals produced in
infected and inflamed tissues could contribute to the process of carcinogenesis
[reviewed by Ohshima and Bartsch, 1994].
There were no published papers on the production of nitric oxide from human buffy
coats in response to H. pylori; therefore, part of this study was designed to examine
the effect of whole cells of H. pylori , OMP and purified adhesin on the ability of
human buffy coats to release nitric oxide. The results showed that whole cells,
OMP or purified adhesin induced nitric oxide and stimulation of human buffy coats
with whole cell bacteria produced higher amount of nitric oxide compared with
purified adhesin or OMP. If nitric oxide plays a role in gastric cancer, these results
suggested that the whole bacteria are the important factor for releasing higher levels
of nitric oxide. In contrast to the results obtained for TNF and IL-6, the lower
concentrations of whole bacteria released higher levels of nitric oxide. If the lower
levels of binding of H. pylori to epithelial cells of donors of group A compared with
group O (chapter 4) reflects the circumstances in vivo, the association between H.
pylori infection and gastric cancer might be related to lower density of colonisation.
6.4.4 Factors contributing to IHD
Decreased levels of nitric oxide have been implicated as a mechanism of primary or
essential hypertension [Snyder and Bredt, 1992; Winquist et al., 1984], The inability
of vessels to vasodilate appears to be related to decreased nitric oxide release and not
to the reduced ability of smooth muscle cells to respond to nitric oxide [Shimokawa
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and Vanhoutte, 1989; Minor et al., 1990]. The degree of endothelial dysfunction
parallels the degree of hypertension. The inability of vessels to vasodilate appears to
be related to decreased nitric oxide release [Shimokawa and Vanhoutte, 1989; Minor
et al., 1990]. The hypothesis tested in this chapter was that cells of blood group A
donors might release more IL-6, TNF or nitric oxide in response to H. pylori
compared with blood group O; however blood group O individuals released
significantly higher amount of IL-6, TNF and nitric oxide compared with blood
group A in response to H. pylori and higher numbers of H. pylori results in lower
levels of nitric oxide. These studies need to be repeated with endothelial cell to
determine if these bacteria or their antigens have a similar effect on induction of
nitric oxide from endothelium.
The association between blood group A and liability to IHD or disease involving
clotting might be explained by the observation that people of blood group A have
higher plasma levels of factor VIII (anti-haemophilic globulin) than do those of
blood group O [reviewed by Mourant and Kopec, 1971] and lower levels of nitric
oxide observed with blood group A responses to H. pylori might results in lower
levels of vasodilator and reduction in desolution of clot formation or platelet
aggregation. The interactions between levels of H. pylori and blood group need to
be assessed further in relation to the production of procoagulant activity reported by
Miragliotta et al., [1989].
Further studies will be required to determine if H. pylori infected patients have high
levels of coagulation factors compared with H. pylori negative patients or if cells of





This chapter summarises the findings and conclusions with reference to the original
objectives to the study, highlights the applications or limitations of the experiments
and methods of analysis used throughout this study and suggests future work.
7.1 Objectives of the study
Epidemiological studies carried out before H. pylori was identified found that non-
secretors and individuals of blood group O were over-represented among patients
with peptic ulcers. This study tested the mechanisms that might explain how these
genetic susceptibility factors could aid the initial colonisation with H. pylori. The
first objective was to assess genetic and life style factors associated with isolation of
H. pylori from patients undergoing gastroscopy. The second objective was to study
how the genetic and environmental factors associated with peptic ulcer disease might
affect binding of H. pylori to epithelial cells. These included the effect of ABO,
Lewis blood groups, smoking and fasting.
7.2 Isolation of H. pylori from gastroscopy patients
Skirrow's medium has been used for the isolation of H. pylori from gastric biopsies,
but is not generally recommended because 14% of the isolates can be inhibited by
nalidixic acid and polymyxin B can inhibit 5% of isolates [Dent and McNulty,
1988]. In this study, one (1/52) of the isolates was inhibited by polymyxin B and
another was inhibited with colistin on primary isolation; therefore for the local
isolates the use of Dent's medium with cefsulodin is recommended for primary
isolation of H. pylori from gastric biopsies.
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The results confirmed the diagnostic value of ELISA for determination of serum IgG
antibodies against H. pylori. The results of the ELISA assay significantly correlated
with the presence of H. pylori in gastric biopsies determined with CLO, microscopy
and culture. In addition, the assay differentiated between patients with and without
peptic ulcers. These results suggest that ELISA might be useful for screening
patients refered for endoscopy thereby reducing the endoscopy list in the clinic. As
H. pylori identification in gastric cancer patients is lower than studies in patients
with peptic ulcers, culture, endoscopy and levels of serum antibodies among patients
with gastric cancer must be carried out to determine how useful serology would be
for screening.
H. pylori positive patients tended to be older than non-infected patients and
prevalence of the infection increased with age. The peak of H. pylori positive
patients was found in the group aged between 50 - 60 years old, whereas the
isolation rate tended to be lower in older patients (> 60 years). This has been
associated with progression of chronic H. pylori gastritis to atrophic gastritis in
elderly people, because severe gastric atrophy seems to make the stomach
inhospitable to H. pylori [Goldschmiedt et al., 1991, Kaneko et al., 1992].
The first objective in the clinical survey was to examine the prevalence of H. pylori
infection in relation to blood groups and secretor status. The study failed to show an
increased prevalence of H. pylori infection among non-secretor patients compared
with secretors, but blood group O was over-represented among patients with
gastroduodenal disease and among patients with H. pylori infection. Larger number
of patients need to be examined as only 52 were infected.
Smokers are more at risk of gastroduodenal disease, but there was no overall
correlation between H. pylori infection and smoking. A significant correlation
between H. pylori infection and smoking was found when results were analysed by
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years of smoking. Thus indicating that longer term smoking is probably a risk
factor for H. pylori infection.
7.3 Detection of H type 2 and Lewis antigens proposed to act as receptors
for H. pylori on the gastric mucosa and cells used in the studies.
Monoclonal antibodies against H type 2, Lea or Le^ bound to buccal epithelial cells,
gastric mucosa and the Kato III cell line. Previous studies of human gastric
carcinoma and normal gastric tissue has demonstrated blood group antigens by
immunohistochemical methods [Sakamoto et al., 1989] and the present study
confirmed binding of monoclonal antibodies to these blood group antigens on the
cell surface of normal gastric tissue by flow cytometry techniques.
Buccal epithelial cells bound the three monoclonal antibodies and those from
individuals of group O had significantly higher binding indices for anti-H type 2
when compared with binding indices for non-0 donors. H type 2, the antigen of
blood group O, is found on the cells of all individuals except the very rare Bombay
phenotype. There were no significant differences in binding indices for anti-Lewis
antibodies for secretors compared with non-secretors. This might be due to cross
reactivity of the anti-Le^ antibody with Lea and the highly variable expression of
Lea on cells of secretors [Saadi et al., 1993]. There were no differences in binding
indices for males compared with females.
Fasting significantly reduced binding to BECs of the monoclonal antibody to H type
2 but not binding of monoclonal antibodies against the Lewis antigens. Binding
indices for all three monoclonal antibodies were significantly lower for cells from
fasting smokers compared with non-smokers. For both smokers and non-smokers
levels of Lewis antigens were higher when the donor were fasting but the differences
were not significant. The significant reduction of anti-H type 2 binding to BEC of
fasting individuals might be related to lower saliva output associated with fasting.
188
This suggestion is supported by observations of other workers in which deprival of
salivary epidermal growth factor (EGF) significantly lowered levels of carbohydrate,
lipids and covalently bound fatty acids, but resulted in higher protein levels when
compared with normal saliva [Sarosiek et al., 1988],
Although fasting and smoking affected binding of monoclonal antibodies, the results
of the bacterial binding studies with BECs indicated that the binding indices for H.
pylori were significantly associated with binding indices for monoclonal antibodies
to H type 2 and Le^ under all the conditions tested. The terminal fucose structure
present on these blood group antigens found in the body fluid of secretors such as
the H type 1 structure found in Lewis*5, A-Lewis*5 or B-Lewis*5 might bind to the
adhesin and reduce colonisation.
Smokers have been shown to have an enhanced adherence of Streptococcus
pneumonia to BECs and Haemophilis influenzae to their pharyngeal cells [Mahajan
and Panhotra, 1989; Raman et al., 1983; Fainstein and Musher, 1979]. While
smoking has been identified as a risk factor for ulcers, the studies of H. pylori
binding to BECs from smokers and non-smokers suggested that smoking will not
result in increased bacterial binding or expression of H type 2 or Lewis blood group
antigens which are proposed to act as receptors if there are similar effects on
epithelial cells lining the gastric mucosa.
7.4 Inhibition of binding of H. pylori with monoclonal against Lea, Le*5 and
H type 2
The second objective was to determine if in addition to Le*5 previously identified as
a receptor for H. pylori [ Boren et al., 1993], Lea or H type 2 could also act as
receptors for the bacteria. There was evidence that receptors for H. pylori on gastric
mucosa cells contained fucose [Falk et al., 1993]. Boren et al [1993] found no
strong evidence for the involvement of fucose-containing blood group antigens other
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than Leb in binding of H. pylori in their model system in which binding of the
bacteria to tissue sections was assessed microscopically [Boren et al., 1993]. In
contrast, the results of this study indicate that pretreatment of cells with monoclonal
antibodies to H type 2, Lewisa or Lewis'3 are capable of inhibiting H. pylori binding
to Kato III and BEC cells in suspension detected by flow cytometry binding studies.
The results suggested that H type 2, Lea and Leb might be receptors for H. pylori on
the gastric mucosa and that H type 2 found on almost all individuals is a key receptor
for H. pylori
7.5 Direct evidence for H type 2, Lea and Leb to act as receptors for
H. pylori
Studies in which bacterial binding is inhibited by pretreatment of target cells with
polyclonal or monoclonal antibodies to the putative receptor have been criticised in
that the inhibition of bacterial binding might be due to stearic hindrance. The
antibodies are binding an epitope near the receptor and blocking access of the
bacteria.
Direct binding of biotinylated H type 2, Lea and Leb to whole bacteria, OMP and
purified adhesin provided complementary evidence that these antigens act as
receptors for H. pylori. The microtitre spectrophotometric method provided a rapid,
quantitative and reliable assay for screening the clinical isolates to determine what
proportion of bacteria bound the blood group antigens. The assay has proved
sensitive, reproducible and was used to demonstrates binding of there antigens to all
51 isolates tested. The use of direct attachment of biotinylated blood group antigens
to the OMP, purified adhesin and to the intact whole cell for H. pylori NCTC 11637
showed binding of H type 2 to be significantly greater than Leb and Lea. These
results also correlated with the amount of the 61 kDa adhesin obtained by affinity
purification from the three antigens.
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H. pylori expresses multiple adhesins on the cell surface such as the 20 kDa, 25 kDa
and 59 kDa haemagglutinin components [Evans et al., 1993; Huang et al., 1992].
The results suggested that the 61 kDa protein a stably expressed adhesin is a major
adhesin by which H. pylori binds to epithelial cells. The majority of strains bound H
type 2, Leb and Lea in a pattern similar to that of NCTC 11637.
7.6 ABO blood groups and susceptibility to diseases associated with H. pylori
infection
7.6.1 Peptic ulcers
Many bacterial pathogens that infect various mucosal sites colonise these surfaces by
adhering to specific receptors in the mucus layer and to glycoconjugates on epithelial
cells [Wadstrom and Trust., 1984]. The ability of a pathogen to adhere to host
structures is often pivotal in the subsequent establishment of infection . It has been
demonstrated that density of colonisation is related to inflammatory responses,
epithelial damage and duodenal ulcer among patients infected with H. pylori
[Atherton et al., 1996].
7.6.1.1 Blood group and density of colonisation
The increased susceptibility of group O individuals to peptic ulcer disease might be
due to enhanced binding of H. pylori to the H type 2 expressed in higher levels on
cells of group O. Both secretors and non-secretors express H type 2 on their cells
and secretors express Leb in mucus. If the terminal fucose structure present on H
type 2 is a major receptor, antigens found in body fluids of secretors with the
terminal fucose on the type 1 precursor chain (H type 1, Lewisb, A-Lewisb or B-
Lewisb) might bind to the adhesin and reduce density of colonisation.
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7.6.1.2 Blood group and inflammatory responses
Whole cells, OMP and the purified adhesin were able to stimulate human huffy coats
to release TNF, IL-6 and NO. The results suggest that the adhesin might also play
an important role in induction of inflammatory responses during H. pylori infection
as well as adherence to the epithelial cells. Blood group O buffy coats released
significantly higher amounts of IL-6, TNF and nitric oxide compared with
leukocytes from group A donors.
7.6.2 Susceptibility of blood group A to gastric cancer
Chronic infection and inflammation have been recognised as risk factors for a
variety of human cancers and it has been proposed that active oxygen species such as
superoxide anion, hydrogen peroxide and hydroxyl radical generated in inflammed
tissues can cause injury to target cells and also damage DNA. There is now
increasing evidence to suggest that nitric oxide (NO) and its derivatives produced by
activated phagocytes may also play a role in the multistage carcinogenesis process
[reviewed by Ohshima and Barsch, 1994], Ascorbic acid is thought to confer
protection against neoplasia by scavenging nitrites, preventing the formation of
potentially carcinogenic N-nitroso compounds and reactive oxygen metabolites, and
by inhibition of the synthesis of DNA, RNA, and protein in tumour cells [reviewed
by Goldstone et al., 1996]. Gastric juice levels of ascorbic acid showed a
significant rise after eradication of H. pylori infection [Sobala et al., 1993]. When
ascorbic acid scavenges reactive oxygen metabolites, ascorbyl radicals are generated
with the increased release of reactive oxygen species in gastritis, higher
concentrations of ascorbyl radicals are found in the gastric mucosa of subjects with
H. pylori infection compared with control subjects [Drake et al., 1995]
Direct evidence comes from the finding of enhanced gastric mucosal nitric oxide
synthase activity in H. pylori positive patients [Rachmilewitz et al., 1994] and nitric
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oxide synthase gene expression in human macrophage lines is enhanced by soluble
proteins from H. pylori [Chi et al., 1994]. There were no published papers on the
production of nitric oxide from human buffy coats in response to H. pylori ;
therefore, part of this study was designed to examine the effect of whole cells of H.
pylori , OMP and purified adhesin on the ability of human buffy coats to release
nitric oxide. The results showed that both whole cells, OMP or purified adhesin
induced nitric oxide and stimulation of human buffy coats with whole bacteria
produced higher amounts of nitric oxide compared with purified adhesin or OMP. If
nitric oxide plays a role in gastric cancer, these results suggested that the whole
bacterium is the important factor for releasing higher levels of nitric oxide. The
finding that lower concentrations of bacteria resulted in higher levels of nitric oxide
production indicates that the association between H. pylori infection and gastric
cancer might be related to lower density of colonisation. If the results of binding
observed in an in vitro studies reflect colonisation in vivo, this might contribute to
the increased susceptibility of blood group A individuals to gastric cancer.
7.6.3 Susceptibility of blood group A to ischaemic heart disease
Mendall and colleagues found that seropositivity for H. pylori conferred a twofold
increased risk of coronary heart disease [Mendall et al., 1994], and Morgando and
colleagues observed an increase in the risk of myocardial infarction at younger ages
for patients with H. pylori infection as judged by presence of antibodies in the blood
[Morgando et al., 1995]. This study supports previous observations that IHD
patients had a significantly higher prevalence of H. pylori antibodies. It differs in
that it examined levels of antibodies, and controlled for undiagnosed heart disease in
the age and sex matched comparison group assessed in the analysis of results. These
results are additional evidence that chronic infection with H. pylori might be a factor
contributing to heart disease.
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Epidemiological studies of IHD identified an association between blood group A and
myocardial infarction and also with thrombosis [summarised by Mourant et al.,
1978]. The opposite was observed in this study; there were more blood group O
individuals who died from of IHD compared with group A but this was not
significant. The hypothesis that group A is more likely to survive from a heart attack
and group O more likely to die needs to be examined with larger numbers of
subjects.
H. pylori infection could contribute to increased risk of IHD by increasing
fibrinogen levels [Patel et al., 1994], and these bacteria also produce a tissue factor
with procoagulant activity which can convert fibrinogen to fibrin [Miragliotta et al.,
1989]. The association between blood group A and susceptibility to IHD or disease
involving clotting might be explained by the observation that people of blood group
A have higher plasma levels of factor VIII (anti-haemophilic globulin) than do
individuals of blood group O [reviewed by Mourant et al., 1978] and the lower
levels of nitric oxide observed with blood group A buffy coat responses to H. pylori
might results in lower levels of vasodilator and reduction in desolution of clot
formation or platelet aggregation.
If vitamins with anti-oxidant effects are involved in controlling damage due to the
response of inflammatory cells to the bacteria, lower levels of vitamin C found in
gastric juice of patients infected with H. pylori might contribute to the pathogenic
process. These levels return to normal following eradication of the bacteria [
Banerjee et al., 1994], The lower levels of vitamin C observed in the winter




Analysis of H. pylori isolates from different diseases (peptic ulcers, gastric cancer
and IHD) for their abilities to stimulate buffy coats from different blood groups to
release inflammatory mediators could further clarify host-parasite interactions
underlying epidemiological observations.
There are a number of interactions between genetic and environmental risk factors
associated with diseases in which H. pylori is implicated that need to be explained.
Reactive oxygen radicals are thought to contribute to modification of serum lipids
that could contributes to atherosclerosis [Carpenter et al., 1995]. The lower levels of
ascorbic acid observed in the gastric juice of patients infected with H. pylori
[Banerjee et al., 1994] needs to be considered in relation to infection and diet in the
aetiology of both cancer and heart disease. Further studies are planned to assess
levels of ascorbic acid in serum in relation to IHD and IgG levels to H. pylori.
Additional studies are needed to define the role of H. pylori in IHD or diseases
involving clotting abnormalities and to determine if there is a correlation between H.
pylori infection and coagulation factor levels.
The interaction between respiratory virus infections, H. pylori infection, dietary
habits and fibrinogen levels need to be assessed in relation to the winter peak in
deaths due to IHD.
Smoking is reported to reduce levels of prostaglandins which are major protective
factors in gastric and duodenal mucosa against injury. H. pylori infected patients
had low amounts of prostaglandin compared with non-infected patients [Goren et al.,
1989; Silecchia et al., 1994]; therefore, further studies are required to determine if
reduced prostaglandin levels are associated with increased binding and colonisation
by H. pylori or with control of inflammatory responses.
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If the adhesin that binds H type 2 and Lewis antigens is found on strains from
different geographical areas, it could be considered as a candidate vaccine
component to prevent H. pylori colonisation. Identification of the role of H type 2
and Lewis antigens as receptors for H. pylori also raises the possibility of anti-
adhesin therapy with synthetic forms of these antigens for reduction and/or reversal
of bacterial binding. If significant antibiotic resistance develops among H. pylori
isolates this might become a major therapeutic approach.
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In the last month, have you had symptoms of:
1 Heartburn Yes/ No mild/ moderate / severe
2 Tummy pain Yes / No mild / moderate/ severe
3 Indigestion Yes / No mild / moderate / severe
What treatments has your doctor given to you in the past one
year?
Antacids ( Yes/ No )
Dosage / day
Cimetidine ( Tagamet ) ( Yes / No )
Dosage mg/day
Ranitidine ( Zantac ) ( Yes / No )
Dosage mg/day
Omeprazole ( Yes / No )
Dosage mg/day
What treatments are you taking now to relieve your symptoms?
Dosage /day
Have you been on any antibiotic treatment over the past three
months?
Yes / No
If yes to above, name the antibiotic
duration of treatment
condition treated for
Have you taken any painkiller in the past three months?
Yes / No
If yes, name the painkiller
dosage
condition treated for
Are you taking any painkiller regularly ?
Yes / No
If yes, name the painkiller
dosage
condition treated for
What other medical conditions are you known to suffer from?
Have you had an operation on you stomach ?
Yes / No
If yes, do you know what was done ?
Are you taking low dose aspirin for heart condition or stroke?
Yes/ No If yes, dosage mg/day
Do you visit your dentist regularly?
Yes / No
If yes, please circle the following:
Every 6 months/ every year / every 2 year
When did you last have dental treatment?
Do you have any dentures?
Yes / No If yes, is it full / partial ?
How often do you clean your teeth?
More than twice per day ( Yes/ No )
Twice per day ( Yes/ No )
Once per day ( Yes / No )
Less than once per day ( Yes / No )
Do you use dental floss regularly?
Yes / No
What is your job?
Does your partner work ? ( Yes / No )
If yes, what is his or her job?
Do you smoke? ( Yes / No )
If yes,
How many cigarretes a day?
How many ounces of tobacco a day?
How long have you smoked for?
Are you an ex-smoker? Yes / No
If yes, when did you stop ?
How much alcohol do you drink in a week?
units
( a pint of lager is equivalent to 2 units; a glass of wine and a











Gastric:( Ulcer is defined as lesion of at least 5mm in diameter
with depth; specify size, number and location of ulcer if
present. )
Duodenum:
CLO: ( Biopsy must be taken within 5 cm of antrum )
Positive/ Negative.
HISTOLOGIC FINDINGS:
( Two biopsy are each taken from gastric antrum, body and
duodenum even if ulcer is absent. Biopsy must be taken from
gastric ulcer if present.)
Body:
Antrum:
Duodenum
